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A B S T R A C T
Background
Intermittent claudication (IC) is a symptom of peripheral arterial disease (PAD) and is associated with high morbidity and mortality.
Pentoxifylline, one of many drugs used to treat IC, acts by decreasing blood viscosity, improving erythrocyte flexibility and promoting
microcirculatory flow and tissue oxygen concentration. Many studies have evaluated the efficacy of pentoxifylline in treating individuals
with PAD, but results of these studies are variable. This is an update of a review first published in 2012.
Objectives
To determine the efficacy of pentoxifylline in improving the walking capacity (i.e. pain-free walking distance and total (absolute,
maximum) walking distance) of individuals with stable intermittent claudication, Fontaine stage II.
Search methods
For this update, the Cochrane Vascular Group Trials Search Co-ordinator searched the Specialised Register (last searched April 2015)
and the Cochrane Register of Studies (2015, Issue 3).
Selection criteria
All double-blind, randomised controlled trials (RCTs) comparing pentoxifylline versus placebo or any other pharmacological interven-
tion in patients with IC Fontaine stage II.
Data collection and analysis
Two review authors separately assessed included studies,. matched data and resolved disagreements by discussion. Review authors
assessed the methodological quality of studies by using the Cochrane ’Risk of bias’ tool and collected results related to pain-free walking
distance (PFWD) and total walking distance (TWD). Comparison of studies was based on duration and dose of pentoxifylline.
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Main results
We included in this review 24 studies with 3377 participants. Seventeen studies compared pentoxifylline versus placebo. In the seven
remaining studies, pentoxifylline was compared with flunarizine (one study), aspirin (one study), Gingko biloba extract (one study),
nylidrin hydrochloride (one study), prostaglandin E1 (two studies) and buflomedil and nifedipine (one study). The quality of the
evidence was generally low, with large variability in reported findings.. Most included studies did not report on random sequence
generation and allocation concealment, did not provide adequate information to allow selective reporting to be judged and did not
report blinding of assessors. Heterogeneity between included studies was considerable with regards to multiple variables, including
duration of treatment, dose of pentoxifylline, baseline walking distance and participant characteristics; therefore, pooled analysis was
not possible.
Of 17 studies comparing pentoxifylline with placebo, 14 reported TWD and 11 reported PFWD; the difference in percentage
improvement in TWD for pentoxifylline over placebo ranged from 1.2% to 155.9%, and in PFWD from -33.8% to 73.9%. Testing
the statistical significance of these results generally was not possible because data were insufficient. Most included studies suggested
improvement in PFWD and TWD for pentoxifylline over placebo and other treatments, but the statistical and clinical significance of
findings from individual trials is unclear. Pentoxifylline generally was well tolerated; the most commonly reported side effects consisted
of gastrointestinal symptoms such as nausea.
Authors’ conclusions
Given the generally poor quality of published studies and the large degree of heterogeneity evident in interventions and in results,
the overall benefit of pentoxifylline for patients with Fontaine class II intermittent claudication remains uncertain. Pentoxifylline was
shown to be generally well tolerated.
Based on total available evidence, high-quality data are currently insufficient to reveal the benefits of pentoxifylline for intermittent
claudication.
P L A I N L A N G U A G E S U M M A R Y
Pentoxifylline for intermittent claudication
Background
Atherosclerosis, or hardening of the arteries, results in narrowing and blockage of the arteries and can reduce the blood supply to the
legs, causing peripheral arterial disease. Intermittent claudication (IC) is a cramp-like pain felt in the leg muscles that is brought on by
walking and is relieved by standing still or resting. Pentoxifylline is a drug that is used to relieve IC while improving people’s walking
capacity. It decreases blood viscosity and improves red blood cell flexibility, promoting microcirculatory blood flow and increasing
oxygen in the tissues. This review looked at all available evidence from randomised controlled trials on the efficiency of pentoxifylline
for treatment of IC.
Study characteristics and key results
This review included 24 studies with 3377 participants (current until April 2015). Seventeen studies compared pentoxifylline with
placebo, and the remaining studies compared pentoxifylline with flunarizine (one study), aspirin (one study), Gingko biloba extract
(one study), nylidrin hydrochloride (one study), prostaglandin E1 (two studies) and buflomedil and nifedipine (one study). Large
differences between included studies in how investigators measured and reported study findings made it impossible to combine results.
Most of the included studies suggested mild to moderate improvement in pain-free walking distance and total walking distance
for pentoxifylline over placebo (and other treatments, which included Gingko biloba, buflomedil, iloprost, nylidrin, aspirin and
prostaglandin E1). The statistical significance of findings from individual trials was unclear, and researchers observed large variability
between studies in the effects of pentoxifylline. The most commonly reported side effects were gastrointestinal symptoms, mainly
nausea, and the drug was well tolerated.
Quality of the evidence
The quality of included studies was generally low, and very large variability between studies was noted in reported findings including
duration of trials, doses of pentoxifylline and distances participants could walk at the start of trials. Most included studies did not report
on randomisation techniques or how treatment allocation was concealed, did not provide adequate information to permit judgement
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of selective reporting and did not report blinding of outcome assessors. Given all these factors, the role of pentoxifylline in intermittent
claudication remains uncertain, although this medication was generally well tolerated by participants.
B A C K G R O U N D
Description of the condition
Intermittent claudication (IC) is a cramp-like pain felt in the leg
muscles that is brought on by walking, is relieved by rest and is
a result of reduced circulation (NICE 2012). Intermittent clau-
dication is a common presentation of peripheral arterial disease
(PAD) caused by atherosclerosis. From 2000 to 2010, the number
of people living with PAD increased across all age groups by a
mean of 23.51% (Fowkes 2013). These data include high-income
countries, as well as low- and middle-income countries. Peripheral
arterial disease is a progressive disease associated with significant
morbidity and mortality. Themain cause of mortality is associated
cerebrovascular and coronary artery disease. Patients with IC have
reduced quality of life and increased risks of stroke and myocardial
infarction (NICE 2011).
Description of the intervention
Primary health care plays an important role in the treatment of
individuals with intermittent claudication. First steps in treating
IC include conservative risk factor control, exercise therapy and
pharmacotherapy (Tendera 2011). Revascularisation intervention,
in the form of open or endovascular surgery, is usually reserved for
incapacitating disease (Bachoo 2010; Fowkes 1998). In one study,
63% of newly diagnosed claudicants were treated by general prac-
titioners with lifestyle advice or drugs, or both; only 37% required
referral to hospital specialists (Meijer 2002). Understanding treat-
ment options and their effectiveness is vital for controlling the
disease at an early stage and preventing its progression.
Different types of medications have been used for treatment of
IC. Vasodilators and antiplatelets reduce the chance of blood clots
at the blockage site (Wong 2011); other drugs help reduce the
symptoms of claudication, improve walking distance and reduce
disability associatedwith the condition (de Backer 2012; deBacker
2013; Robertson 2013).
How the intervention might work
Pentoxifylline is a vasoactive drug that has been authorised for
the medical treatment of individuals with IC. Pentoxifylline de-
creases blood viscosity, improves erythrocyte flexibility and pro-
motes microcirculatory flow, while increasing tissue oxygen con-
centration. It is a methylxanthine derivative that works by inhibit-
ing the enzyme phosphodiesterase and by potentiating the effects
of endogenous prostacyclin, a prostaglandin that possesses anti-ag-
gregatory, fibrinolytic (decreased fibrinogen concentrations) and
vasodilatory properties and increases cyclic adenosine monophos-
phate (cAMP) levels in red blood cells, platelets and arterial cell
walls (Micromedex 2002).
Why it is important to do this review
Intermittent claudication is a marker of increased morbidity and
mortality, and treating symptoms is becoming ever more impor-
tant with the increased prevalence of PAD. Previous studies and
reviews have evaluated the efficacy of pentoxifylline in the treat-
ment of IC and peripheral vascular disease, compared with other
treatment options including other pharmacological interventions
and exercise, yielding variable results (Bedenis 2014; Lane 2014;
Moher 2000; Stevens 2012). Continued evaluation of pentoxi-
fylline through evidence-based systematic reviewswill result in im-
proved understanding of available pharmacological interventions
for IC.
Recently, the National Institute for Health and Care Excellence
(NICE) recommended naftidrofuryl oxalate as the leading phar-
macological treatment for IC on studies of effectiveness and costs
(NICE 2011; NICE 2012). In this review, we will not address
cost-effectiveness.
O B J E C T I V E S
To determine the efficacy of pentoxifylline in improving the walk-
ing capacity (i.e. pain-free walking distance and total (absolute,
maximum) walking distance) of individuals with stable intermit-
tent claudication, Fontaine stage II (Fontaine 1954).
M E T H O D S
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Criteria for considering studies for this review
Types of studies
We included all double-blind, randomised controlled trials of pen-
toxifylline versus placebo or versus other pharmacological inter-
ventions. We excluded comparisons with diet, exercise or surgery.
We excluded single-blind and open studies.
Types of participants
We included patients with symptoms of stable IC (no change in
symptoms for six months), Fontaine stage II (Fontaine 1954), due
to peripheral vascular disease. We excluded those with symptoms
of critical ischaemia (rest pain, skin ulcers or gangrene) or who
had undergone previous surgical or percutaneous catheter inter-
ventions.
Types of interventions
We included studies that compared pentoxifylline versus placebo
or some other pharmacological intervention and lasted at least
four weeks. We excluded comparisons with surgery, angioplasty
or exercise. We included all doses and routes of administration of
pentoxifylline.
Types of outcome measures
Primary outcomes
Walking capacity is one of the most important outcome measures
used to assess intermittent claudication.
According to Moher 2000, walking capacity can be assessed by
• pain-free walking distance (PFWD) or initial claudication
distance (ICD), which is the distance walked on a treadmill
before the onset of pain; and
• total walking distance (TWD) or absolute claudication
distance (ACD), which is the maximum or absolute distance
walked on a treadmill.
Secondary outcomes
• Ankle-brachial pressure index (ABI).
• Quality of life, as measured by questionnaires.
• Side effects.
In this review, we excluded outcome measures such as blood vis-
cosity and microcirculation.
Search methods for identification of studies
We applied no language restrictions in our searches, and we sought
translation of non-English trials.
Electronic searches
For this update, the Cochrane Vascular Group Trials Search Co-
ordinator (TSC) searched the Specialised Register (last searched
April 2015) and the Cochrane Register of Studies (CRS) (http:/
/www.metaxis.com/CRSWeb/Index.asp) (2015, Issue 3), which
is part of the Cochrane Library (www.cochranelibrary.com). See
Appendix 1 for details of the search strategy used in searching
the CRS. The Specialised Register is maintained by the TSC and
is constructed from weekly electronic searches of MEDLINE,
EMBASE, CINAHL, AMED, and through handsearching rele-
vant journals. The full list of the databases, journals and confer-
ence proceedings which have been searched, as well as the search
strategies used are described in the Specialised Register section of
the Cochrane Vascular Group module in the Cochrane Library (
www.cochranelibrary.com).
Searching other resources
We reviewed the reference lists of all relevant, identified studies.
Data collection and analysis
Selection of studies
Two review authors (KS and RF) used the eligibility criteria pro-
vided above to independently assess all potentially relevant articles
identified by the search strategy described.We resolved differences
by consensus.
Data extraction and management
KS and RF collected information from each included trial. Infor-
mation collected included trial design, participant characteristics,
inclusion and exclusion criteria, interventions and controls used,
treatment periods, methods of assessment and PFWD and TWD
results. We also collected data on the secondary outcomes of an-
kle-brachial pressure index (ABI), quality of life and side effects.
Assessment of risk of bias in included studies
For the update of this review, two review authors (RF and KS)
assessed the quality of included studies using the ’Risk of bias’
tool described in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011); we assessed allocation (selection
bias), blinding (performance bias and detection bias), incomplete
outcome data (attrition bias), selective reporting (reporting bias)
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and other potential sources of bias. We assigned a score of high
risk, unclear risk or low risk of bias, according to Higgins 2011.
Measures of treatment effect
We planned to pool the data on pain-free walking distance
(PFWD) and absolute (total) walking distance (TWD) from each
trial to arrive at an overall estimate of the effectiveness of phar-
macological interventions. We planned to calculate the percent-
age change in walking distance before and after the interventions.
When possible, we planned to calculate the mean difference be-
tween pentoxifylline and control groups.
Unit of analysis issues
For all included studies, the unit of randomisation was the indi-
vidual participant.
Dealing with missing data
When data were not available or were missing, we contacted study
authors to request missing data.
Assessment of heterogeneity
We planned to perform all analyses on an intention-to-treat ba-
sis. We planned to evaluate outcome data for appropriateness for
the meta-analysis on the basis of heterogeneity by using the Chi2
test and the I2 statistic, both of which describe the percentage of
variability in estimates of effect that is due to heterogeneity rather
than to chance. If the I2 value was greater than 50%, we planned
to evaluate data for heterogeneity. We planned to use a random-
effects model for meta-analyses if no reason was found for hetero-
geneity. We planned to use a fixed-effect model if the I2 value was
lower than 50%.
Assessment of reporting biases
We planned to assess reporting bias by using funnel plots if more
than 10 studies were included in the meta-analysis.
Data synthesis
We intended to perform a pooled, fixed-effect model meta-analy-
sis of included trials with subgroup analyses using variables such
as duration of treatment and dose and route of administration.
However, in the light of clinical heterogeneity, we judged that a
pooled meta-analysis was not appropriate.
Subgroup analysis and investigation of heterogeneity
We anticipated that trials would not be homogeneous. Therefore,
we planned to perform a subgroup analysis of included trials using
variables such as duration of treatment and dose and route of
administration.
Sensitivity analysis
We planned to perform sensitivity analyses to evaluate the effects
on meta-analysis of studies of low quality due to risk of bias, as
well as studies with unclear inclusion criteria or methods.
R E S U L T S
Description of studies
Results of the search
See Figure 1 for details of the search results. For this update of
the review, we identified three additional reports of studies. One
study was considered to be not relevant, another was excluded
(Singh 2009) and the third consisted of an abstract that correlated
with a study previously listed in ’Ongoing Studies’ (Schellong
2012), from which data are now available. This review update
identified 24 included studies and 39 excluded studies. It should
be noted that several excluded studies from the previous version
of the review have been removed, as they are now considered not
relevant.
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Figure 1. Study flow diagram.
Included studies
For details of included studies, see Characteristics of included
studies.
We included a total of 24 studies with 3377 participants. Four-
teen studies compared pentoxifylline versus placebo alone (Belcaro
2002; Bollinger 1977; Cesarone 2002b; De Sanctis 2002a; De
Sanctis 2002b; Di Perri 1983; Donaldson 1984; Ernst 1992;
Gallus 1985; Kiesewetter 1988; Lindgarde 1989; Porter 1982a;
Porter 1982b; Volker 1978), one versus flunarizine (Perhoniemi
1984), one versus aspirin (Ciocon 1997), one versusGingkobiloba
extract (GBE) (Bohmer 1988), one versus nylidrin hydrochloride
(Accetto 1982) and two versus prostaglandin E1 (PGE1) (Hepp
1992; Schellong 2012). Two studies compared pentoxifylline ver-
sus placebo and cilostazol (Dawson 2000; Lee 2001), one com-
pared pentoxifylline versus placebo and iloprost (Creager 2008)
and one compared pentoxifylline versus buflomedil and nifedip-
ine (Chacon-Quevedo 1994).
The treadmill protocol for assessment of PFWD and TWD var-
ied between studies. The treadmill speed most commonly used
in included studies was 3 km/h, with gradients ranging from 0%
(Accetto 1982) to 5% (Bohmer 1988), 10% (Chacon-Quevedo
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1994) and 12% (Belcaro 2002; Cesarone 2002b; De Sanctis
2002a; De Sanctis 2002b; Schellong 2012). Other studies used
a treadmill speed of 3.2 km/h - three with a gradient of 12.5%
(Bollinger 1977; Lee 2001; Lindgarde 1989) and two starting at a
0% gradient and gradually increasing the inclination during test-
ing (Creager 2008; Dawson 2000). One study used a treadmill
speed of 3.6 km/h at 0% gradient (Perhoniemi 1984), and two
used a treadmill speed of 4 km/h - one at a 0%gradient (Donaldson
1984) and the other at a 10% gradient (Gallus 1985). Three stud-
ies used different units of speed; Di Perri 1983 used a walking
test of 120 steps per minute on a horizontal treadmill, and Porter
1982a and Porter 1982b used a speed of 1.5 mph - both at a 7%
gradient. Four studies did not provide information on the tread-
mill protocol used (Ernst 1992; Hepp 1992; Kiesewetter 1988;
Volker 1978).
Two studies reported use of an exercise programme (Bollinger
1977; Ernst 1992). Remaining studies did not report use of an
exercise programme, or reported that no specific instructions were
given to participants.
Excluded studies
We excluded 39 studies because they did not meet the inclusion
criteria. See theCharacteristics of excluded studies table for reasons
for exclusion. In brief, 18 studies were not double-blinded (Bieron
2005; Dawson 1999; Dettori 1989; Hepp 1996; Milio 2003;
Milio 2006; Panchenko 1997; Pignoli 1985; Regenthal 1991;
Reilly 1987; Rodin 1998; Rodin 1998a; Scheffler 1991; Scheffler
1994; Shustov 1997; Singh 2009; Strano 2002; Triebe 1992),
two included participants with critical limb ischaemia (Schubotz
1976; Thomson 1990), four included participants with Fontaine
stage III and did not present results separately for the differ-
ent Fontaine stages (Kellner 1976; Roekaerts 1984; Strano 1984;
Tonak 1977), fourwere short-term studies (Farkas 1993;Rudofsky
1987; Rudofsky 1988; Rudofsky 1989), 10 described non-rele-
vant outcomes (Ciuffetti 1991; Ehrly 1986; Ehrly 1987; Fossat
1995; Guest 2005; Incandela 2002; Luk’Janov 1995; Poggesi
1985; Tsang 1994; Wang 2003) and one used variable doses of
pentoxifylline (Horowitz 1982).
Risk of bias in included studies
Risk of bias in included studies is summarised in Figure 2 and
Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Selection bias was deemed to involve low risk in only two stud-
ies (Dawson 2000; Lee 2001). Another study (Perhoniemi 1984)
indicated low risk of bias for random sequence generation. For
all other studies, available information was insufficient to permit
judgement of low or high risk of bias.
Blinding
Blinding of participants and personnel was achieved in 12 studies
(Belcaro 2002; Bollinger 1977; Creager 2008; Dawson 2000; Di
Perri 1983; Gallus 1985; Kiesewetter 1988; Lee 2001; Lindgarde
1989; Porter 1982a; Porter 1982b; Schellong 2012), which there-
fore were classed as having low risk of bias. Eleven studies were
classed as having unclear risk of bias (Accetto 1982; Bohmer 1988;
Cesarone 2002b; Chacon-Quevedo 1994; De Sanctis 2002a;
De Sanctis 2002b; Donaldson 1984; Ernst 1992; Hepp 1992;
Perhoniemi 1984; Volker 1978), mainly because of insufficient
reporting, and one study (Ciocon 1997) was deemed to be at high
risk of bias because different treatment regimens were provided
for the study medication.
For all but one study (Gallus 1985), risk of bias for blinding of
outcome assessment (detection bias) was classed as unclear because
of insufficient reporting. For the study by Gallus 1985, blinding
of outcome assessment was deemed to present low risk of bias
because study authors reported that results were withheld from
investigators during the study.
Incomplete outcome data
For most included studies, no evidence suggested incomplete out-
come data (Belcaro 2002; Bohmer 1988; Bollinger 1977; Chacon-
Quevedo 1994; Ciocon 1997; Dawson 2000; Donaldson 1984;
Ernst 1992; Gallus 1985; Hepp 1992; Lee 2001; Perhoniemi
1984; Porter 1982a; Porter 1982b; Schellong 2012; Volker 1978),
or information was insufficient to indicate whether outcome data
were missing (Accetto 1982; Cesarone 2002b; Creager 2008; De
Sanctis 2002a; De Sanctis 2002b; Di Perri 1983; Kiesewetter
1988; Lindgarde 1989).
Selective reporting
For all included studies except Kiesewetter 1988 and Schellong
2012, available information, such as a study protocol, was insuffi-
cient to permit judgement of selective reporting. Kiesewetter 1988
was judged at high risk of bias because TWD results were reported
in the abstract but were not mentioned in the remainder of the
paper, either as an outcome variable or as a result. Schellong 2012
was judged to have low risk, as all outcomes described in the Clin-
icalTrials.gov protocol were reported.
Other potential sources of bias
Most studies were deemed free of other bias (Accetto 1982; Belcaro
2002; Bohmer 1988; Cesarone 2002b; Ciocon 1997; Donaldson
1984; Ernst 1992; Gallus 1985; Hepp 1992; Kiesewetter 1988;
Lee 2001; Lindgarde 1989; Perhoniemi 1984; Porter 1982a; Porter
1982b; Volker 1978). All other studies (Chacon-Quevedo 1994;
Creager 2008; Dawson 2000; De Sanctis 2002a; De Sanctis
2002b; Di Perri 1983; Schellong 2012) were determined to have
unclear risk of bias for a variety of reasons, such as unclear re-
porting (Chacon-Quevedo 1994; De Sanctis 2002a; De Sanctis
2002b; Di Perri 1983) or sponsoring of the study by a pharma-
ceutical company (Creager 2008; Dawson 2000; Schellong 2012).
One study was assigned high risk of bias because of differences in
clinical baseline data between study groups (Bollinger 1977).
Effects of interventions
Pentoxifylline versus placebo
A total of 17 studies compared pentoxifylline versus placebo (
Belcaro 2002; Bollinger 1977; Cesarone 2002b;De Sanctis 2002a;
De Sanctis 2002b; Di Perri 1983; Donaldson 1984; Ernst 1992;
Gallus 1985; Kiesewetter 1988; Lindgarde 1989; Porter 1982a;
Porter 1982b; Volker 1978). Two of these studies also compared
pentoxifylline versus cilostazol (Dawson 2000; Lee 2001), and one
compared pentoxifylline with iloprost (Creager 2008).
Pain-free walking distance (PFWD)
A total of 11 studies (Cesarone 2002b; Creager 2008; Dawson
2000; Donaldson 1984; Ernst 1992; Gallus 1985; Kiesewetter
1988; Lindgarde 1989; Porter 1982a; Porter 1982b; Volker 1978)
that compared pentoxifylline with placebo measured PFWD. The
duration of these studies varied from four to 40 weeks. Most stud-
ies used a pentoxifylline dose of 1200 mg per day. We analysed
studies according to duration and dose levels. See Table 1 for de-
tails on PFWD by study. Results for PFWD are reported as per-
centage improvement in mean PFWD during treatment for both
pentoxifylline and placebo groups. To formally compare improve-
ment in PFWD between groups, data on both mean improve-
ment and standard deviation of mean improvement were required.
Of the 11 included studies, only one (Lindgarde 1989) presented
data on standard deviation of the percentage change in PFWD;
therefore, statistical analysis was performed only for this study. A
pooled analysis was not conducted because data were lacking lev-
els of heterogeneity between included studies were high with re-
gards to multiple variables, including duration of treatment, dose
of pentoxifylline, baseline walking distance and participant char-
acteristics.
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Four weeks
At four weeks, Volker 1978 was the study of shortest duration;
investigators included 50 participants (25 in each arm) and gave
a dose of 1200 mg pentoxifylline. Baseline PFWD was 331 m for
the pentoxifylline group compared with 230 m for the placebo
group. At the end of the study, mean PFWD for participants who
received pentoxifylline improved by 40.3% compared with 26.0%
for those given placebo, for a difference of 14.3% in favour of
pentoxifylline.
Eight weeks
Three studies had a duration of eight weeks (Donaldson 1984;
Gallus 1985; Kiesewetter 1988). One study (Donaldson 1984)
used 600 mg of pentoxifylline, and the other two used 1200 mg.
Gallus 1985 was a cross-over study consisting of two periods of
eight weeks.
Donaldson 1984 included 40 participants in each group. The
increase in mean PFWD in the pentoxifylline group, from 108.2
m to 119.3 m (10.3%), was 22.6% less than in the placebo group,
from 97.1 m to 129 m (32.9%).
Gallus 1985 performed a cross-over study. Fifty participants were
recruited, but only 38 finished the study and were included in the
analysis (19 participants in each group). Study authors reported
no statistically significant improvement in PFWD for pentoxi-
fylline compared with placebo but did not present the results of
significance tests. In the first phase of the study (eight weeks),
PFWD in the pentoxifylline group improved by 7.7% more than
in the placebo group (76.0% vs 68.3%). After the second portion
of the study, participants treated with pentoxifylline in phase 1
and placebo in phase 2 showed a decrease of 9.4% in PFWD after
cross-over. Those treated with placebo in phase 1 and pentoxi-
fylline in phase 2 improved by 10.4% after cross-over.
Kiesewetter 1988 compared 1200 mg of pentoxifylline versus
placebo over eight weeks in a study with 40 participants. Results
showed that PFWD in the pentoxifylline group improved by 44m
(43.6%) comparedwith 3m (3.1%) in the placebo group. Authors
of this paper did not present data on baseline walking distance for
the two groups.
Twelve weeks
One study, which lasted 12 weeks (Ernst 1992), used 1200 mg
pentoxifylline daily and included 40 participants (20 in each arm).
Both groups of participants exercised regularly for one hour twice
a week. Study authors stated that both groups showed significant
improvement in walking distance, although they did not present
the results of statistical tests. The pentoxifylline group improved
by 152.8% (144 m to 364 m) and the placebo group by 186.6%
(134 m to 384 m), for a difference of 33.8% in favour of placebo.
Twenty-four weeks
All studies with a duration of 24 to 26 weeks (six months)
used 1200 mg of pentoxifylline (Creager 2008; Dawson 2000;
Lindgarde 1989; Porter 1982a; Porter 1982b).
In a large multi-centre study, Creager 2008 compared pentoxi-
fylline versus placebo (and vs various doses of iloprost) over six
months. In this study, 430 participants were randomly assigned
to five groups: iloprost 50 µg (87 participants), iloprost 100 µg
(86 participants), iloprost 150 µg (87 participants), pentoxifylline
1200 mg (86 participants) and placebo (84 participants). Only
214 participants ( 50%) completed the entire six months of the
study. Three hundred seventy participants were included in what
was called an intention-to-treat analysis on the basis that they had
received at least one dose of the study drug and had undergone at
least one follow-up test, that is, within two to four weeks.Walking
distance in the pentoxifylline group improved by 34.3% from a
baseline PFWD of 118 m compared with a 21.2% improvement
in the placebo group from a baseline PFWD of 120 m. Overall,
pentoxifylline improved PFWDby 13.1%more than placebo, but
this difference could not be analysed statistically because data were
insufficient. Study authors reported that after one month, the dif-
ference between groups was statistically significant, but P values
for significance results were not provided.
Dawson 2000 included 232 participants in the pentoxifylline
group and 239 in the placebo group. The pentoxifylline group im-
proved by 12.8%more than the placebo group (60.3% vs 47.5%).
Lindgarde 1989 included 76 participants in the pentoxifylline
group and 74 in the placebo group. Results showed a net improve-
ment for pentoxifylline of 20% (95% confidence interval (CI)
16.3 to 23.7) over placebo (80% vs 60%). This improvement was
statistically significant (P value < 0.0001).
Porter 1982a was a relatively large study with no intention-to-treat
analysis. Gillings 1987 performed an intention-to-treat analysis
on data from the Porter 1982a study. Initially, Porter 1982a dou-
ble-blinded 128 participants (including one who was randomly
assigned twice) but included only 82 participants in the analysis
(pentoxifylline 42, placebo 40); remaining participants were with-
drawn from the study because of side effects and loss to follow-up.
In the initial analysis, PFWD distance improved in the pentoxi-
fylline group from 111 m to 195 m (75.7%) and in the placebo
group from 117 m to 180 m (53.8%), yielding a statistically sig-
nificant difference of 21.9% (P value = 0.18) in favour of pentox-
ifylline. Gillings 1987 included 124 participants who had follow-
up data (63 in the pentoxifylline group and 61 in the placebo
group). In this intention-to-treat analysis, PFWD improved in the
pentoxifylline group by 47% and in the placebo group by 26%
(difference of 21% in favour of pentoxifylline). The authors of
this paper did not present data on end-of-trial PFWD.
Another, smaller study by Porter et al. (Porter 1982b) consisted
of 22 participants (11 in each arm). In this study, PFWD in the
pentoxifylline group improved by 73.9%more than in the placebo
group (108.8% vs 34.9%, respectively).
10Pentoxifylline for intermittent claudication (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Forty weeks
Cesarone 2002 used 1600 mg of pentoxifylline daily for 40 weeks.
The pentoxifylline group consisted of 88 participants, and the
placebo group 90 participants. Total PFWD in the pentoxifylline
group improved from 43 m to 166 m (286%), and in the placebo
group from 42 m to 155 m (269%), for a small difference of 17%
in favour of pentoxifylline.
Total walking distance (TWD)
A total of 14 studies comparing pentoxifylline with placebo
(Belcaro 2002; Bollinger 1977; Cesarone 2002b; Creager 2008;
Dawson 2000; De Sanctis 2002a; De Sanctis 2002b; Di Perri
1983; Ernst 1992; Gallus 1985; Lee 2001; Lindgarde 1989; Porter
1982a; Porter 1982b) assessed TWD. The duration of these stud-
ies ranged from eight weeks to 52 weeks. See Table 2 for details on
TWD by study. As was done for PFWD, TWD was reported as
percentage change in mean TWD from baseline to end of study
for pentoxifylline and placebo groups separately, and as the differ-
ence in percentage change between groups. Again, data on mean
change in TWD and standard deviation of the change were re-
quired to compare improvement in TWD between groups. In all
14 included studies, trial authors failed to report the standard de-
viation of the percentage change in mean TWD, so a statistical
analysis could not be performed. Meta-analysis of TWD results
for pentoxifylline compared with placebo was not performed for
reasons similar to those described for PFWD results.
Eight weeks
Four studies had a duration of eight weeks. One study used 600
mg (Bollinger 1977), one 800 mg (Lee 2001) and two 1200 mg
pentoxifylline (Di Perri 1983; Gallus 1985).
In Bollinger 1977, the sample size was 19 participants (10 pentox-
ifylline and nine placebo) with a dose of 600 mg of pentoxifylline.
The quality of the study was poor; initially 26 participants were
included, but results for only 19 were included in the analysis. No
intention-to-treat analysis was performed. The two groups varied
in terms of duration of claudication and extent of disease. Par-
ticipants in the pentoxifylline group had more unilateral disease,
and more bilateral and extensive disease was noted in the placebo
group. All participants in this study were advised to stop smoking
and to walk daily for at least one hour. Investigators reported im-
provement with pentoxifylline over placebo of 155.9% (208.4%
vs 52.5%).
Lee and colleagues published two reports on the same study (Lee
2001; Lee 2001a). Only a very slight difference was apparent be-
tween reports in that the sample size was larger by two partici-
pants in the later report (17 in the pentoxifylline group, 16 in the
placebo group and 17 in the cilostazol group). Results from Lee
2001 are included in both reports. TWD improved in the pentox-
ifylline group from 114 m to 147 m (28.9%) compared with 116
m to 121 m (4.3%) in the placebo group, for an overall difference
of 24.6% in favour of pentoxifylline.
Di Perri 1983 examined 1200 mg of pentoxifylline in 24 partic-
ipants using a cross-over design (12 participants in each group
over two periods of eight weeks). A 61% increase in TWD was
described for the pentoxifylline group compared with 3.5% for
the placebo group after the first period. This was confirmed after
the cross-over, when the pentoxifylline group again increased by
61% compared with an increase of 1.9% in the placebo group.
In Gallus 1985, also a cross-over study, TWD showed a pat-
tern similar to PFWD. After the first phase of the study, TWD
improved by 33.3% in the pentoxifylline group compared with
13.5% in the placebo group (difference of 19.8% in favour of
pentoxifylline). After the cross-over phase, participants who were
treated with pentoxifylline in phase 1 and placebo in phase 2 im-
proved by just 1.88% over those treated with placebo before pen-
toxifylline.
Twelve weeks
One study reportedfindings at 12weeks (Ernst 1992). Both groups
of participants also received regular exercise, for one hour twice a
week. TWD in the pentoxifylline group (1200mgdaily) improved
from 166 m to 504 m (203.6%) compared with improvement in
the placebo group from 151 m to 420 m (178.1%), yielding a
difference of 25.5% in favour of pentoxifylline.
Twenty-four to twenty-six weeks
Six studies (Belcaro 2002;Creager 2008;Dawson 2000; Lindgarde
1989; Porter 1982a; Porter 1982b) had a duration of 24 to 26
weeks (six months). Apart from Belcaro 2002, which used a dose
of 1600 mg, and Creager 2008, which used 400 mg, studies used
1200 mg of pentoxifylline.
Belcaro 2002 compared 1600 mg daily of pentoxifylline versus
placebo. TWD improved in the pentoxifylline group from 56 m
to 161 m (187.5%), and TWD in the placebo group improved
from 59 m to 103 m (74.6%), showing a difference of 112.9% in
favour of pentoxifylline.
Creager 2008 presented baseline TWD and percentage improve-
ment rather than TWD at the end of the study. The pentoxi-
fylline versus placebo result showed significant improvement for
pentoxifylline of 13.9% (from baseline TWD of 316 ± 191 m)
compared with placebo, which resulted in improvement of only
3.3% (from baseline TWD of 292 ± 161 m), for a difference of
10.6% in favour of pentoxifylline.
Dawson 2000 did not show significant improvement in TWD for
pentoxifylline over placebo (29.4% vs 28.2%).
In Lindgarde 1989, TWD improved by 50% in the pentoxifylline
group compared with 29% in the placebo group, for a difference
of 21% in favour of pentoxifylline. Data on TWD at the end of
the study were not presented, and improvement in TWD between
groups could not be analysed statistically.
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In the original analysis of Porter 1982a, TWD improved from 172
m to268m (55.8%) in the pentoxifylline group and from181m to
250 m (38.1%) in the placebo group, for a net difference of 17.7%
in favour of pentoxifylline. InGillings 1987 (the intention-to-treat
analysis of the Porter 1982a study) and Reich 1984 (a publication
based on the Porter 1982a study), TWD in the pentoxifylline
group improved by 32%comparedwith 20% in the placebo group
(difference of 12% in favour of pentoxifylline). Data on TWD at
the end of this study were not presented.
In Porter 1982b, the net improvement in TWD observed in the
pentoxifylline group over the placebo group was 66.5% (P value
= 0.002). TWD in the pentoxifylline group improved by 69.4%
compared with just 2.9% in the placebo group.
Forty weeks
Investigators in one study with a duration of 40 weeks gave 1600
mg of pentoxifylline daily (Cesarone 2002b). This study included
88 participants in the pentoxifylline group and 90 in the placebo
group.Very large improvement inTWDof 229.9%was seen in the
pentoxifylline group (from 87 ± 11 m to 287 ± 340 m) compared
with 83.7% (from 98 ± 14 m to 180 ± 120 m) in the placebo
group, for a net difference of 146.2%.
Fifty-two weeks
Two studies were reported by De Sanctis in 2002 (De Sanctis
2002a; De Sanctis 2002b). The former study looked at partici-
pants with a baseline TWD between 50 m and 200 m, and the
latter study examined participants with a greater baseline TWD
(> 500 m). Investigators in both studies administered 1800 mg of
pentoxifylline daily.
In De Sanctis 2002a, each group consisted of 60 participants ini-
tially, but only 56 of those in the pentoxifylline group and 45
in the placebo group completed the study. In this study, baseline
walking distance was short, and the effect of pentoxifylline was
more prominent. The pentoxifylline group improved by 304.5%
(66 ± 13 m to 267± 38 m), and the placebo group by 180.6% (67
± 11 m to 188 ± 19 m), for a net difference of 123.9% in favour
of pentoxifylline.
De Sanctis 2002b included 98 participants in the pentoxifylline
group (75 of whom completed the study) and 96 in the placebo
group (60 of whom completed the study). Significant improve-
ment in TWD from baseline was reported in both groups, and the
pentoxifylline group improved by 39.1% more than the placebo
group. In the pentoxifylline group, TWD increased by 70.2%
(554 ± 66 m to 943 ± 78 m) versus 31.1% (576 ± 71 m to 755 ±
67 m) in the placebo group.
Ankle-brachial pressure index (ABI)
Five studies comparing pentoxifylline versus placebo (Bollinger
1977; Dawson 2000; Donaldson 1984; Gallus 1985; Lee 2001)
measured ABI. Three of these looked only at pre-exercise or resting
ABI (Bollinger 1977; Dawson 2000; Lee 2001), and two looked at
both pre-exercise and post-exercise ABI (Donaldson 1984; Gallus
1985). Authors of all five studies presented mean ABI at baseline
and at endof treatment for both pentoxifylline andplacebo groups.
However, as the standard deviation for the change in ABI was not
presented in any of the studies, statistical analysis could not be
conducted to compare improvement in ABI. Furthermore, none
of the five studies reported results of their own statistical tests. ABI
results were not amenable to meta-analysis because of lack of data,
differences in ABI measurements and differences in pentoxifylline
doses and study duration.
In Bollinger 1977, pre-exercise ABI improved from 0.57 to 0.64
in the pentoxifylline group, and in the placebo group it dropped
from 0.62 to 0.59 on the basis of measurements from the posterior
tibial artery. Trialists stated that although a tendency toward better
results was evident in the pentoxifylline group, results were not
statistically significant.
Dawson 2000 reported that ABI increased in the pentoxifylline
group from 0.66 ± 0.21 at baseline to 0.71 ± 0.24 at 24 weeks. In
the placebo group, ABI did not improve (0.68 ± 0.42 at baseline,
0.67 ± 0.19 at 24 weeks). Study authors reported that improve-
ment in ABI in the pentoxifylline group was not significantly dif-
ferent from that in the placebo group but did not present the level
of significance.
In Lee 2001,mean pre-exercise ABI improved in the pentoxifylline
group from 0.66 ± 0.13 to 0.7 ± 0.14, and in the placebo group
from 0.69 ± 0.12 to 0.71 ± 0.13. Study authors reported no sig-
nificant changes in ABI across all groups (including cilostazol).
In Donaldson 1984, no difference in ABI was reported in the
pentoxifylline group nor in the placebo group before and after
exercise. In the pentoxifylline group, pre-exercise ABI remained
the same at 0.52 ± 0.26 before and after treatment. Post-exercise
ABI dropped from 0.3 ± 0.27 before treatment to 0.27 ± 0.25
after treatment. In the placebo group, pre-exercise ABI improved
from 0.52 ± 0.25 to 0.57 ± 0.24, and in the treatment group from
0.32 ± 0.26 to 0.34 ± 0.30. Study authors stated that none of these
results were statistically significant (P values not presented).
Gallus 1985 reported no differences in the pentoxifylline group
nor in the placebo group before and after exercise at the end of
a cross-over study. In the pentoxifylline group, pre-exercise ABI
improved from 0.59 ± 0.14 before treatment to 0.61 ± 0.16 after
treatment; and post-exercise ABI dropped from 0.13 (range 0.03
to 0.60) before treatment to 0.10 (range 0.02 to 0.55) after treat-
ment. In the placebo group, pre-exercise ABI remained similar at
0.59 ± 0.14 before and 0.59 ± 0.16 after treatment. Post-exer-
cise ABI increased slightly, from 0.13 (range 0.03 to 0.60) before
treatment to 0.14 (range 0.03 to 0.63) after treatment. None of
these results were reported as statistically significant, and the level
of significance used was not reported in the paper.
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Quality of life
Three studies comparing pentoxifylline versus placebo reported
on quality of life (Creager 2008; Dawson 2000; Volker 1978).
Both Dawson 2000 and Creager 2008 reported no differences
between treatment groups in Short Form 36 (SF36) scores. Scores
on the walking impairment questionnaire (WIQ) - a measure of
degree of handicap caused by the disease - were similar between
pentoxifylline and placebo groups in the Dawson 2000 study.
Creager 2008 reported that stair climbing was the only domain
of the WIQ questionnaire that significantly improved when the
pentoxifylline group and the placebo group were compared (9%
increase in score; P value = 0.04).
Volker 1978 reported that in the pentoxifylline group, 18 partici-
pants reported improvement and seven reported no improvement.
Six participants in the placebo group showed improvement, 18
showed no improvement and one showed a decline. Differences
between treatment groups were statistically significant (P value <
0.01).
Side effects
Nine studies comparing pentoxifylline versus placebo reported
on side effects (Belcaro 2002; Cesarone 2002b; Creager 2008;
Dawson 2000; De Sanctis 2002b; Lee 2001; Porter 1982a; Porter
1982b; Volker 1978).
Belcaro 2002, Cesarone 2002b, De Sanctis 2002b and Lee 2001
reported that no side effects or serious side effects were observed.
Creager 2008 reported that the most common adverse events ob-
served in the pentoxifylline group were headache at 19%, pain
in extremity at 14% and dyspepsia at 13%, compared with 16%,
7% and 5%, respectively, in the placebo group. The frequency of
premature discontinuation of pentoxifylline was similar to that of
placebo. Serious adverse events were reported in 14% of the pen-
toxifylline group compared with 17% of the placebo group.
Dawson 2000 reported that the withdrawal rate from placebo was
16% (38/239) compared with 26% (60/232) from pentoxifylline.
Most of the commonly reported side effects, such as headache
and diarrhoea, were similar between pentoxifylline and placebo
groups, except for pharyngitis, which was reported by 14% in the
pentoxifylline group and 7% in the placebo group.
Porter 1982a reported that 55% (37/67) of participants in the
pentoxifylline group and 39% (24/61) of those in the placebo
group reported side effects. Side effects reported were mainly gas-
trointestinal complaints; the most commonly reported complaint
was nausea.
Porter 1982b reported that no participants discontinued as a re-
sult of drug-related side effects, which were minimal in the two
treatment groups. According to trialists, the only statistically sig-
nificant (P value not presented) side effect was nausea, which was
reported by seven pentoxifylline participants.
Volker 1978 reported similar numbers of side effects in the two
treatment groups. In the pentoxifylline group (25 participants),
two participants reported headaches, two dizziness, two stomach
pains and two itching, and in the placebo group (25 participants),
two participants reported headaches, two dizziness and three stom-
ach pains.
Pentoxifylline versus flunarizine
Perhoniemi 1984 compared 1200mgof pentoxifylline daily versus
15 mg of flunarizine daily over six months (three-month cross-
over design). Seventeen participants started on flunarizine, and 14
started on pentoxifylline.
Pain-free walking distance
In Perhoniemi 1984, PFWD increased for both pentoxifylline and
flunarizine groups (P value < 0.01) when compared with baseline,
but no statistically significant difference was found between pen-
toxifylline and flunarizine groups (Table 3).
Total walking distance
In Perhoniemi 1984, statistically significant improvement in
TWDwas noted in both groups (43% for pentoxifylline and 18%
for flunarizine), but no statistically significant differences were ob-
served between groups (Table 4).
Ankle-brachial pressure index
Nodifference inABIwas foundbyPerhoniemi 1984 betweenbase-
line measurements (0.63 ± 0.20) and measurements after treat-
ment (pentoxifylline 0.63 ± 0.19; flunarizine 0.62 ± 0.20), nor
between treatment groups.
Quality of life
Perhoniemi 1984 did not measure quality of life.
Side effects
In Perhoniemi 1984, 32 participants reported side effects (tired-
ness, diarrhoea, gastrointestinal symptoms, sweating, itching and
allergic reactions), but no statistically significant differences were
noted between flunarizine and pentoxifylline groups. One partic-
ipant in the pentoxifylline group discontinued the study because
of gastrointestinal symptoms.
Pentoxifylline versus aspirin
Ciocon 1997 compared 325 mg of aspirin versus 1200 mg of
pentoxifylline over six weeks. Each group included 45 participants.
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Pain-free walking distance
Ciocon 1997 did not measure PFWD.
Total walking distance
Baseline TWD was one mile for the pentoxifylline group. This
increased to two miles after the treatment period, showing im-
provement of 100%. The aspirin group showed improvement of
50%, from 0.8 miles to 1.2 miles. Study authors reported that
50% improvement in TWD after treatment with pentoxifylline
versus placebo was statistically significant (P value < 0.05) (Table
4).
Ankle-brachial pressure index
ABI testing showed very slight improvement in the pentoxifylline
group, from 0.6 ± 0.1 to 0.7 ± 0.2, and in the aspirin group, ABI
remained similar (0.6 ± 0.3 at baseline, 0.6 ± 0.5 after treatment).
Quality of life
Ciocon 1997 did not measure quality of life.
Side effects
Ciocon 1997 did not measure side effects.
Pentoxifylline versus Ginkgo biloba extract (GBE)
Bohmer 1988 compared pentoxifylline with GBE. A total of 27
participants were included: 13 received 1200 mg of pentoxifylline
daily, and 14 received 160 mg of GBE, over 24 weeks.
Pain-free walking distance
In Bohmer 1988, PFWD significantly improved in both groups
after treatment, but no statistically significant difference was ob-
served between treatment groups. PFWD increased in the pentox-
ifylline group from 80.1 m to 325.6 m (P value < 0.05), and in
the GBE group from 94.6 m to 327.5 m (P value < 0.01) (Table
3). A statistically significant difference between treatment groups
was not detected, according to Bohmer 1988.
Total walking distance
TWD significantly improved in both groups after treatment, but
no statistically significant difference was observed between treat-
ment groups. TWD increased in the pentoxifylline group from
189.5 m to 472.3 m (P value < 0.01), and in the GBE group
from 203 m to 436.5 m (P value < 0.01) (Table 4). A statistically
significant difference between treatment groups was not detected,
according to Bohmer 1988.
Ankle-brachial pressure index
Bohmer 1988 reported that ABI increased slightly in both treat-
ment groups but did not present the data.
Quality of life
Bohmer 1988 did not measure quality of life.
Side effects
Bohmer 1988 did not measure side effects.
Pentoxifylline versus nylidrin hydrochloride
Accetto 1982 compared 400 mg of pentoxifylline daily versus 3
mg of nylidrin hydrochloride daily, over eight weeks.
Pain-free walking distance
Accetto 1982 did not measure PFWD.
Total walking distance
Compared with baseline, TWD increased in the pentoxifylline
group from 132.6 m to 193.4 m (46.7%), and in the nylidrin
group from 163.4 m to 168.9 m (1%) (P value = 0.006). Study
authors also expressed TWD in seconds, with the pentoxifylline
group improving from 160 seconds at baseline to 240 seconds af-
ter treatment. TWD in the nylidrin group at baseline was 197 sec-
onds, and after treatment 220 seconds. Improvement in walking
distance was observed in 17 of 23 in the pentoxifylline group and
in 11 of 24 in the nylidrin hydrochloride (HCl) group (Table 4).
Accetto 1982 reported that at the end of treatment, a significant
difference favoured pentoxifylline (P value = 0.006).
Ankle-brachial pressure index
Accetto 1982 did not measure ABI.
Quality of life
Accetto 1982 did not measure quality of life.
Side effects
Accetto 1982 reported that 6 of 23 pentoxifylline participants and
3 of 24 nylidrin HCl participants reported side effects. Most of
these were gastrointestinal in nature, and all were transient and of
mild severity.
14Pentoxifylline for intermittent claudication (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pentoxifylline versus prostaglandin E1 (PGE1)
Two studies compared pentoxifylline versus prostaglandin E1 (
Hepp 1992; Schellong 2012).
Hepp 1992 compared intravenous pentoxifylline (400 mg) versus
intravenous PGE1 (80 mg) over four weeks. Schellong 2012 com-
pared pentoxifylline (600 mg twice daily for a total of 1200 mg)
versus intravenous PGE1 (20 µg alprostadil) over a total of eight
weeks, which was broken down into two four-week treatment pe-
riods; four weeks of PGE1 injections given daily were followed
by four weeks of bi-weekly injections. It should be noted that for
the Schellong 2012 study, all data were retrieved from the Clini-
calTrials.gov website, which offered no actual walking distances -
only ratios - and no findings of statistical analysis. It is hoped that
future publications planned for this study will provide additional
information on data and collection methods.
Pain-free walking distance
Median PFWD increased in the pentoxifylline group from 72 m
to 133 m (85%) compared with an increase in the PGE1 group
from 80 m to 175 m (119%) (Table 3). According to Hepp 1992,
the difference between treatments was statistically significant (P
value < 0.001).
Results from Schellong 2012 were presented as ratios for PFWD at
the specified time point compared with baseline PFWDwith stan-
dard deviations. After the first four-week treatment period (daily
PGE1), the ratio of PFWD compared with baseline for pentoxi-
fylline-treated participants was 1.58 ± 2.59, and for PGE1-treated
participants 1.58 ± 1.92. After the second four-week treatment pe-
riod (bi-weekly PGE1), the PFWDratiowas 1.98±3.61 compared
with baseline for pentoxifylline-treated participants, and 2.60 ±
12.22 for those treated with PGE1. After six months of post-treat-
ment follow-up, the ratio was 2.36 ± 2.69 for pentoxifylline, and
2.27 ± 3.00 for PGE1.
Total walking distance
Median TWD increased in the pentoxifylline group from 115 m
to 190 m (65%) and in the PGE1 group from 129 m to 230 m
(78%) (Table 4). According toHepp 1992, the difference between
treatments was statistically significant (P value < 0.01).
As with PFWD, Schellong 2012 reported TWD as a ratio of the
time point measurement compared with baseline. Following the
first four-week treatment period (daily PGE1), the ratio of TWD
compared with baseline for pentoxifylline-treated participants was
1.43 ± 1.34, and for PGE1-treated participants 1.39 ± 0.53. After
the second four-week treatment period (bi-weekly PGE1), TWD
ratio compared with baseline was 1.76 ± 1.78 for pentoxifylline-
treated participants and 1.64 ± 0.86 for those treated with PGE1.
Six months after treatment, the ratio for pentoxifylline was 1.99
± 1.61, and for PGE1 1.89 ± 1.40.
Ankle-brachial pressure index
Hepp 1992 and Schellong 2012 did not measure ABI.
Quality of life
Hepp 1992 did not measure quality of life.
Schellong 2012 measuredmean changes in quality of life using the
Peripheral Arterial Occlusive Disease 86 quality of life question-
naire (PAVK 86) and reported changes from baseline to the end
of the six-month follow-up period for eight domains, along with
standard deviations. A change in the pain domain of -0.41 ± 0.58
was noted for the pentoxifylline group, and -0.28 ± 0.57 for the
PGE1 group. Functional status showed a change of -0.35 ± 0.57
for the pentoxifylline group, and -0.26 ± 0.58 for the PGE1 group.
A change in the anxiety domain of -0.22 ± 0.66 was reported for
the pentoxifylline group, and -0.20 ± 0.64 for the PGE1 group.
For the pentoxifylline group, a change of -0.12 ± 0.53 in mood
and a smaller change of -0.04 ± 0.45 in social life were observed,
and the PGE1 group showed changes of -0.06 ± 0.48 and -0.09 ±
0.43, respectively. For expectation of treatment, investigators re-
ported an increase of 0.11 ± 0.49 for the pentoxifylline group and
0.07 ± 0.51 for the PGE1 group. State of general health during the
last week showed a change of -0.48 ± 1.98 for the pentoxifylline
group, with change in quality of life of -0.39 ± 2.20 during the
last week, and the PGE1 group recorded mean changes of -0.43 ±
1.83 and -0.36 ± 2.09, respectively.
Side effects
Hepp 1992 reported that one PGE1 participant experienced nau-
sea, and two others discontinued study medication for reasons un-
related to the medication. In total, six participants discontinued
pentoxifylline treatment early because of nausea. In both treat-
ment groups, no cardiovascular side effects were observed.
Schellong 2012 reported 17 total serious adverse events in 28
(5.96%) participants in the pentoxifylline group and 19 among
276 (6.88%) participants in the PGE1 group, which included,
but were not limited to, coronary artery disease, angina, carotid
artery stenosis and peripheral arterial occlusive disease (although
it is noted that many of these are not necessarily events, but rather
co-morbidities with events during the trial). Other adverse events
were reported in 55 of 285 (19.30%) participants in the pentox-
ifylline group and in 60 of 276 (21.74%) in the PGE1 group;
these included, but were not limited to, vertigo, gastrointestinal
symptoms, peripheral oedema and hyperlipidaemia.
Pentoxifylline versus cilostazol
Two studies compared pentoxifylline versus cilostazol (Dawson
2000; Lee 2001).
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Pain-free walking distance
One study (Dawson 2000) examined PFWD. This study com-
pared 232 participants who received 1200 mg of pentoxifylline
versus 227 who received 200 mg of cilostazol daily over 24 weeks.
PFWD in the cilostazol group improved by 75.8% (124 ± 81 m to
218 ± 149 m) compared with 60.3% in the pentoxifylline group
(126 ± 79 m to 202 ± 139 m), with a net difference of 15.5%.
As standard deviations were not presented in the paper, it was not
possible to compare improvement in PFWD between treatment
groups (Table 3).
Total walking distance
Both studies examined TWD (Table 4). In Dawson 2000, TWD
improved in the cilostazol group by 45.2% (241 ± 123 m to 350 ±
209 m) compared with the pentoxifylline group, which improved
by 29.4% (238 ± 119 m to 308 ± 183 m), with a net difference
of 15.8%. Statistical analysis comparing improvement in TWD
between treatment groups could not be performed because data
on standard deviations were insufficient.
Lee 2001 compared 17 participants who received 800 mg of pen-
toxifylline daily versus another 17 who received 200 mg of cilosta-
zol. The pentoxifylline group improved by 29% (114 ± 51 m to
147 ± 81 m) versus 30% improvement in the cilostazol group
(111 ± 30 m to 145 ± 53 m). Differences in improvement between
treatment groups could not be tested statistically because datawere
insufficient.
Ankle-brachial pressure index
Lee 2001 reported that ABI in the cilostazol group dropped from
0.73 ± 0.12 to 0.69 ± 0.11, and the pentoxifylline group improved
from 0.66 ± 0.13 to 0.7 ± 0.14. Study authors stated that none
of these results were statistically significant, although they did not
present test results. Dawson 2000 reported that ABI increased
in the cilostazol group from 0.66 ± 0.18 at baseline to 0.70 ±
0.18 at 24 weeks, and in the pentoxifylline group, ABI increased
from 0.66 ± 0.21 to 0.71 ± 0.24. ABI after 24 weeks was not
statistically significantly different between treatment groups (P
value not presented).
Quality of life
Lee 2001 did not measure quality of life. Dawson 2000 reported
that no treatment significantly affected SF36 and WIQ scores.
Side effects
Dawson 2000 reported that rates of withdrawal due to adverse ef-
fects were similar in pentoxifylline (43/232) and cilostazol groups
(36/227). Headache, diarrhoea and abnormal stools were signifi-
cantly more common among participants receiving cilostazol than
among those receiving pentoxifylline or placebo. Dawson 2000 re-
ported that these adverse events were generally mild to moderate,
were self-limiting and did not appear to affect the dropout rate.
Pentoxifylline versus iloprost
Creager 2008 compared iloprost (50 µg, 100 µg and 150 µg) versus
pentoxifylline (1200 mg) and placebo over six months.
Pain-free walking distance
PFWD increased by 24%, 28.9% and 31.2% for the iloprost 50
µg, 100 µg and 150 µg groups, respectively, and the increase for the
pentoxifylline group was 34.3% (Table 3). Creager 2008 reported
no significant differenceswhen comparing treatment groups versus
placebo (P value = NS) but did not report on differences between
iloprost and pentoxifylline.
Total walking distance
Iloprost comparisons showed that TWD increased in 50 µg, 100
µg and 150 µg groups by 7.7%, 8.8% and 11.2%, respectively.
None of these changes were significant. Improvement with pen-
toxifylline over placebo was significant, as reported above, but tri-
alists did not report on differences between iloprost and pentoxi-
fylline (Table 4).
Ankle-brachial pressure index
Creager 2008 did not measure ABI.
Quality of life
Quality of life was measured using the WIQ and the SF36. Ac-
cording to Creager 2008, the SF36 showed no differences between
treatment groups, and the WIQ showed significant differences
only in stair climbing between iloprost and placebo, and between
pentoxifylline and placebo. Again, trialists did not report on dif-
ferences between iloprost and pentoxifylline.
Side effects
Creager 2008 reported side effects for the iloprost, pentoxifylline
and placebo groups. The most common side effects in the pen-
toxifylline group were headache (19%), pain in extremity (14%)
and dyspepsia (13%), and side effects in the iloprost groups were
mainly headache, vasodilation or flushing, pain in extremity, jaw
pain, nausea and diarrhoea. For most adverse events, severity in-
creased with increasing dose of iloprost.
16Pentoxifylline for intermittent claudication (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pentoxifylline versus buflomedil and nifedipine
Chacon-Quevedo 1994 compared pentoxifylline (1200 mg daily)
versus buflomedil (600 mg daily) and nifedipine (60 mg daily)
over 90 days (three months). A total of 45 individuals participated
in the study (15 in each group).
Pain-free walking distance
PFWD increased in the pentoxifylline group from 109 ± 63 m to
194 ± 72 m, for improvement of 78%, compared with buflomedil
(97 ± 73 m to 160 ± 73 m), which showed improvement of 64.9%
and nifedipine (109 ± 56 m to 194 ± 65 m), with 78% improve-
ment (Table 3).
Total walking distance
TWD increased in the pentoxifylline group from 180 ± 67 m to
226 ± 57 m compared with buflomedil (159 ± 76 m to 205 ± 66
m) and nifedipine (186 ± 54 m to 226 ± 49 m) (Table 4).
Chacon-Quevedo 1994 concluded that at 90 days, pentoxifylline
was statistically better than buflomedil but not nifedipine in im-
proving walking distance, but investigators did not specify the
subtype (PFWD or TWD) nor the results of statistical tests.
Ankle-brachial pressure index
Chacon-Quevedo 1994 reported that improvement in ABI for the
pentoxifylline group (0.64 ± 0.14 to 0.75 ± 0.17) was statistically
greater than for the buflomedil or nifedipine group, but study
authors did not provide complete data.
Quality of life
Chacon-Quevedo 1994 did not measure quality of life.
Side effects
Chacon-Quevedo 1994 did not measure side effects.
D I S C U S S I O N
Intermittent claudication (IC) is a symptom of peripheral arte-
rial disease (PAD) that is associated with increased morbidity and
mortality and poor quality of life. It reflects the presence of an un-
derlying disease process that results in narrowing or maybe block-
age of lower limb blood vessels. It is associated with the presence
of atherosclerosis elsewhere in the vascular tree, especially in the
coronary and cerebral circulations.
As this pathology cannot be reversed, the main aims of treatment
are (1) to stop or slow progression of the disease to critical is-
chaemia, to prevent adverse events, and (2) to alleviate the severity
of symptoms to improve quality of life.
It is widely accepted, although at times controversial, that treat-
ment of PAD at the stage of IC is medical, and that revascularisa-
tion is not the treatment of choice. Large numbers of interventions
have been developed. Lifestyle changes and exercise are the basic
essential interventions; they have a significant effect on both dis-
ease progression and symptoms. Other essential drugs like statins
are very important for slowing the disease but have little effect on
the symptoms. Pentoxifylline is one of many drugs used to relieve
symptoms of IC and to improve quality of life.
Summary of main results
In comparing pentoxifylline with placebo, 11 studies reported
pain-free walking distance (PFWD). The duration of studies
ranged from four to 40 weeks, and the pentoxifylline dose from
600 mg to 1600 mg. Baseline PFWD ranged from 27.1 m to 460
m, with large variability in results. One study reported less im-
provement in PFWD over the duration of the trial in the pentoxi-
fylline group than in the placebo group - with a difference as great
as 33.8%. On the other hand, maximum improvement in PFWD
among participants receiving pentoxifylline was 73.9%more than
in those given placebo.
A total of 14 studies reported total walking distance (TWD) as an
outcome when comparing pentoxifylline versus placebo. Studies
varied in duration from eight weeks to 52 weeks, and pentoxi-
fylline dose from 400 mg to 1800 mg, but most studies used 1200
mg. Baseline TWD ranged from 56 m to 678 m, and for PFWD,
results were highly variable. The minimum benefit of pentoxi-
fylline shown was 1%, and the maximum benefit was 155.9%.
In one study, pentoxifylline showed greater improvement in
PFWD when compared with Gingko biloba extract (GBE), bu-
flomedil and iloprost; cilostazol showed greater improvement
when comparedwith pentoxifylline; andprostaglandinE1 (PGE1)
showed greater improvement when compared with pentoxifylline.
Data from the second study, which evaluated PGE1 and pen-
toxifylline, are too limited to allow meaningful conclusions. For
TWD, greater improvement was shown for pentoxifylline than for
nylidrin, GBE and aspirin, and for cilostazol and flunarizine than
for pentoxifylline. PGE1 showed greater improvement in TWD
in one study, and data in the second study are currently too limited
to permit meaningful conclusions.
Pentoxifylline appeared to be well tolerated in most studies, with
gastrointestinal side effects, mainly nausea, reported most com-
monly. These effects appeared mild.
Most included studies suggested improvement in PFWD and
TWD for pentoxifylline over placebo (and other treatments), but
the statistical significance of findings from individual trials is un-
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clear, and pentoxifylline showed no improvement in ABI. It is im-
portant to appreciate the difference between statistical significance
and clinical significance; even when a statistically significant im-
provement is described, improvement of a few metres might not
make much difference to a patient.
Overall completeness and applicability of
evidence
This review shows great variability between trial outcomes with
pentoxifylline treatment. This helps to explain the large number of
studies of pentoxifylline for IC that have beenperformedover three
decades. Positive results in some studies were often only marginal,
and across studies were generally inconsistent, encouraging further
research to attain consistency.
Large variability in the results of studies included in this review
was not unexpected. These studies used different doses of pen-
toxifylline, over variable durations, in different countries and by
various study designs, but the variety of participant characteristics
is most important. Investigators stated that they included individ-
uals with IC Fontaine class II, but baseline walking distance varied
from 27.1 m to 460 m for PFWD, and from 56 m to 678 m for
TWD. This suggests considerable variation in the characteristics
of participant groups across studies. Most researchers stated that
baseline variables were comparable between intervention and con-
trol groups but did not specify these variables.
Only two studies reported use of an exercise programme in addi-
tion to pentoxifylline or comparison treatments. The remaining
studies did not report an exercise programme or indicated that no
formal programme was used. Some studies advised participants to
stop smoking for the duration of the study. Advice on exercise and
smoking appears inconsistent between studies, and effects of this
on overall outcomes and placebo effects are unknown.
Quality of the evidence
We judged the overall quality of the evidence to be low. For most
included studies, the risk of bias is unclear, mainly because insuffi-
cient information is available to permit judgement of low or high
risk of bias. This was the case for selection bias, blinding, detection
bias in particular, attrition bias and bias due to selective reporting.
The quality of the evidence is severely limited by the heterogeneity
of included studies. Study duration varied from four weeks to
52 weeks. Pentoxifylline doses used for the intervention group
varied. Most studies used 1200 mg, but doses from 400 mg to
1800 mg were reported. Variability in outcomes was evident in
that studies assessed PFWD, TWD or both. In addition, different
treadmill protocols that ranged from constant load tests to graded
tests were used to measure PFWD and TWD. Some studies did
not report the treadmill protocol used. PFWD and TWD were
reported asmeans, geometricmeans, seconds to percentage change
from baseline and ratios. Thus we could not perform a pooled
analysis.
Potential biases in the review process
In this systematic review, we identified all randomised controlled
trials (RCTs) that compared pentoxifylline versus placebo or other
pharmacological interventions. Open, cohort and single-blinded
studies were not included because pentoxifylline has been studied
extensively, and research authors identified a considerable number
of RCTs. Comparisons of lifestyle changes and exercise were not
included because no evidence has supported their inclusion in
any treatment plan. As IC is a long-term condition, we included
studies with a minimum duration of four weeks. We believe our
search for RCTs has been comprehensive, and it is unlikely that our
standardised methods of study selection and data extraction could
have introducedmajor bias. Heterogeneity of included studies and
variable presentation of outcomes by trialists (requiring substantial
data imputation) precluded pooling of data.
Agreements and disagreements with other
studies or reviews
A systematic review published in 2012 compared pentoxifylline,
cilostazol and naftidrofuryl oxalate versus placebo, or versus one
another, for the treatment of intermittent claudication in individ-
uals with peripheral arterial disease (Stevens 2012). The Stevens
2012 review included four studies that were also included in
our review - three comparing pentoxifylline versus placebo, and
one comparing pentoxifylline versus cilostazol. Study authors em-
ployed imputation techniques to include study data in meta-anal-
yses that we ourselves did not use because of heterogeneity. Their
results revealed possible increases in both PFWD and TWD for
pentoxifylline groups, with percent changes of 9% (95% credible
interval 2% to 22%) and 11% (95% credible interval 1% to 24%),
respectively. Adverse events were not reported in themeta-analysis,
but with all vasoactive drugs, mild headaches and gastrointestinal
issues were reported, and no increase in cardiovascular events or
deaths was described for pentoxifylline, cilostazol or naftidrofuryl
oxalate. Study authors noted that heterogeneity in quality of life
reporting prevented them from reporting these findings in their
review. However, these data are presented as part of Squires 2010
and Squires 2011, in technology assessment reports written for
theNational Institute for Health and Care Excellence (NICE) and
in a recent study evaluating the cost-effectiveness of various treat-
ments (Meng 2014; NICE 2011; NICE 2012).
Other systematic reviews on pentoxifylline for intermittent clau-
dication have yielded results (Ernst 1994; Frampton 1995) simi-
lar to the findings of this review. Greater improvement in PFWD
and TWD was shown for pentoxifylline versus placebo, but re-
view authors concluded that clinical effects remain unclear and
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may depend on patient characteristics, such as ABI, duration of
intermittent claudication, whether risk factors were addressed and
whether other treatment options had been investigated.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Given the generally poor quality of published studies and the large
degree of heterogeneity apparent among interventions and results,
the overall benefit of pentoxifylline for patients with Fontaine class
II intermittent claudication remains uncertain, but themedication
is generally well tolerated.
High-quality data are currently insufficient to show the benefits
of pentoxifylline for intermittent claudication.
Implications for research
Numerous studies on pentoxifylline for intermittent claudication
over more than 30 years have reported highly variable outcomes.
Whilst this comprehensive review summarises and critiques all
available RCT evidence, and should prove helpful to clinicians
and healthcare professionals in making informed decisions regard-
ing pentoxifylline for the treatment of patients with intermittent
claudication, the role of pentoxifylline in treatment remains un-
certain. However, valuable research resources might be better di-
rected toward discovery of more effective treatments or prevention
measures.
A C K N OW L E D G E M E N T S
We would like to thank Cochrane Vascular for help provided in
updating this review.
R E F E R E N C E S
References to studies included in this review
Accetto 1982 {published data only}
Accetto B. Beneficial hemorheologic therapy of chronic
peripheral arterial disorders with pentoxifylline: results of
double-blind study versus vasodilator-nylidrin. American
Heart Journal 1982;103(5):864–9.
Belcaro 2002 {published data only}
Belcaro G, Nicolaides AN, Griffin M, De Sanctis MT,
Cesarone MR, Incandela L, et al. Intermittent claudication
in diabetics: treatment with exercise and pentoxifylline - a
6-month, controlled, randomized trial. Angiology 2002;53
Suppl 1:39–43.
Bohmer 1988 {published data only}
Bohmer D, Kalinski S, Michaelis P, Szogy A. [Efficacy and
tolerance of Ginkgo biloba extract compared to that of
pentoxifylline in the treatment of patients suffering from
peripheral chronic arterial occlusive disease] [German].
Hers Kreislauf 1988;20(1):5–8.
Bollinger 1977 {published data only}
Bollinger A, Frei CH. Double-blind study of pentoxifylline
against placebo in patients with intermittent claudication.
Pharmatherapeutica 1977;1(9):557–62.
Cesarone 2002b {published data only}
Cesarone MR, Belcaro G, Nicolaides AN, Griffin M,
De Sanctis MT, Incandela L, et al. Treatment of severe
intermittent claudication with pentoxifylline: a 40-week,
controlled, randomized trial. Angiology 2002;53 Suppl 1:
1–5.
Chacon-Quevedo 1994 {published data only}
Chacon-Quevedo A, Eguaras MG, Calleja F, Garcia MA,
Roman M, Casares J, et al. Comparative evaluation of
pentoxifylline, buflomedil, and nifedipine in the treatment
of intermittent claudication of the lower limbs. Angiology
1994;45(7):647–53.
Ciocon 1997 {published data only}
Ciocon JO, Galindo-Ciocon D, Galindo DJ. A comparison
between aspirin and pentoxifylline in relieving claudication
due to peripheral vascular disease in the elderly. Angiology
1997;48(3):237–40.
Creager 2008 {published data only}
Creager MA, Pande RL, Hiatt WR. A randomized trial of
iloprost in patients with intermittent claudication. Vascular
Medicine 2008;13(1):5–13.
Dawson 2000 {published data only}
Dawson DL, Beebe HG, Herd JA, Chinoy DA, Davidson
MH, Hiatt WR, et al. Cilostozol or pentoxifylline for
claudication. Circulation 1998;98 Suppl 1:1–12.
∗ Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd,
Martin JD, Bortey EB, et al. A comparison of cilostazol
and pentoxifylline for treating intermittent claudication.
American Journal of Medicine 2000;109(7):523–30.
Dawson DL, Zheng Q, Worthy SA, Charles B, Bradley
DV Jr. Failure of pentoxifylline or cilostazol to improve
blood and plasma viscosity, fibrinogen, and erythrocyte
deformability in claudication. Angiology 2002;53(5):
509–20.
De Sanctis 2002a {published data only}
De Sanctis MT, Cesarone MR, Belcaro G, Nicolaides AN,
Griffin M, Incandela L, et al. Treatment of intermittent
claudication with pentoxifylline: a 12-month, randomized
trial - walking distance and microcirculation. Angiology
2002;53 Suppl 1:7–12.
19Pentoxifylline for intermittent claudication (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
De Sanctis 2002b {published data only}
De Sanctis MT, Cesarone MR, Belcaro G, Nicolaides AN,
Griffin M, Incandela L, et al. Treatment of long-distance
intermittent claudication with pentoxifylline: a 12-month,
randomized trial. Angiology 2002;53 Suppl 1:13–17.
Di Perri 1983 {published data only}
Di Perri T, Guerrini M. Placebo controlled double blind
study with pentoxifylline of walking performance in patients
with intermittent claudication. Angiology 1983;34(1):40–5.
Donaldson 1984 {published data only}
∗ Donaldson DR, Hall TJ, Kester RC, Ramsden CW,
Wiggins PA. Does oxpentifylline (’Trental’) have a place
in the treatment of intermittent claudication?. Current
Medical Research and Opinion 1984;9(1):35–40.
Donaldson DR, Kester RC, Russell CW, Wiggins PA,
Hall TJ. Does oxpentifylline (Trental) have a place in
the treatment of intermittent claudication?. Clinical
Hemorheology. 1 1981; Vol. 1, issue 5–6:469.
Ernst 1992 {published data only}
Ernst E, Kollar L, Resch KL. Does pentoxifylline prolong
the walking distance in exercised claudicants? A placebo-
controlled double-blind trial. Angiology 1992;43(2):121–5.
Gallus 1985 {published data only}
Gallus AS, Gleadow F, Dupont P, Walsh J, Morley AA,
Wenzel A, et al. Intermittent claudication: a double-blind
crossover trial of pentoxifylline. Australian and New Zealand
Journal of Medicine 1985;15(4):402–9.
Hepp 1992 {published data only}
Hepp W, Von Bary S, Corovic D, Diehm C, Muhe E,
Rudofsky G, et al. Clinical comparison of the effect of
I.U. prostaglandin E1 and I.U. pentoxifylline in patients
with arterial occlusive disease [Vergleich der klinischen
wirksamkeit von i.v. prostaglandin E1 und i.v. pentoxifyllin
bei patienten mit arterieller verschlubkrankheit im stadium
llb nach fontaine]. Vasa. 21 1992; Vol. 21, issue 4:447
Abstract No. 6.3.
Hepp W, Von Bary S, Corovic D, Diehm C, Muhe E,
Rudofsky G, et al. Intravenous prostaglandin E1 versus
pentoxifylline: a randomized controlled study in patients
with intermittent claudication. International Angiology. 14
1995; Vol. 14 Suppl 1:280.
∗ Hepp W, Von Bary S, Corovic D, Diehm C, Muhe E,
Rudofsky G, et al. Therapeutic effectiveness of PGE1
intravenous administered comparising with Pentoxifylline
on intermittent claudication. Angiology 1992;14(2):59–64.
Hepp W, von Bary S, Corovic D, Diehm C, Muhe E,
Rudofsky G, et al. Randomized study comparing the
clinical effectiveness of intravenous prostaglandin E1 and
intravenous pentoxifylline in patients with Fontaine stage
IIb arterial occlusive disease [Randomisierte studie zum
vergleich der klinischen wirksamkeit von i.v. prostaglandin
E1 and i.v. pentoxifyllin bei patienten mit arterieller
verschlubkrankheit im stadium IIb nach fontaine]. Vasa -
Supplementum 1991;33:348–9.
Kiesewetter 1988 {published data only}
Kiesewetter H, Blume J, Jung F, Waldhausen P, Gerhards M.
Intermittent claudication. Increase in walking distance and
improvement of hemorheologic parameters by pentoxifylline
(trental 400). MMW, Munchener Medizinische Wochenschrift
1988;130:357–60.
Lee 2001 {published data only}
Lee TM, Su SF, Hwang JJ, Tseng CD, Chen MF, Lee
YT, et al. Differential lipogenic effects of cilostazol and
pentoxifylline in patients with intermittent claudication:
potential role for interleukin-6. Atherosclerosis 2001;158(2):
471–6.
∗ Lee TM, Su SF, Tsai CH, Lee YT, Wang SS. Differential
effects of cilostazol and pentoxifylline on vascular
endothelial growth factor in patients with intermittent
claudication. Clinical Science 2001;101(3):305–11.
Lindgarde 1989 {published data only}
Lindgarde F, Jelnes R, Bjorkman H, Adielsson G, Kjellstrom
T, Palmquist I, et al. Conservative drug treatment in
patients with moderately severe chronic occlusive peripheral
arterial disease. Scandinavian Study Group. Circulation
1989;80(6):1549–56.
Perhoniemi 1984 {published data only}
Perhoniemi V, Salmenkivi K, Sundberg S, Johnsson R,
Gordin A. Effects of flunarizine and pentoxifylline on
walking distance and blood rheology in claudication.
Angiology 1984;35(6):366–72.
Porter 1982a {published data only}
Gillings D, Koch G, Reich T, Stager WJ. Another look at
the pentoxifylline efficacy data for intermittent claudication.
Journal of Clinical Pharmacology 1987;27(8):601–9.
∗ Porter JM, Cutler BS, Lee BY, Reich T, Reichle FA,
Scogin JT, et al. Pentoxifylline efficacy in the treatment of
intermittent claudication: multicenter controlled double-
blind trial with objective assessment of chronic occlusive
arterial disease patients. American Heart Journal 1982;104
(1):66–72.
Reich T, Cutler BC, Lee BY, Porter JM, Reichle FA, Scogin
JT, et al. Pentoxifylline in the treatment of intermittent
claudication of the lower limbs. Angiology 1984;35(7):
389–95.
Reich T, Gillings D. Effects of pentoxifylline on severe
intermittent claudication. Angiology 1987;38(9):651–6.
Porter 1982b {published data only}
Porter JM, Bauer GM. Pharmacologic treatment of
intermittent claudication. Surgery 1982;92(6):966–71.
Schellong 2012 {published data only}
NCT01263925. Prostaglandin E1 in outpatients with
intermittent claudication. https://clinicaltrials.gov/ct2/
show/NCT01263925.
Schellong S, Baron Von Bilderling P, Grus JD, Lawall H,
Grieger F, Ney U, et al. Intravenous alprostadil treatment
compared to oral pentoxifylline treatment in outpatients
with intermittent claudication: results of a clinical study.
Vasa - Journal of Vascular Diseases 2012;41:78.
20Pentoxifylline for intermittent claudication (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Volker 1978 {published data only}
Volker D. [Treatment of arterial diseases with trental 400.
Results of a double-blind study]. Die Medizinische Welt
1978;29(32):1244–7.
References to studies excluded from this review
Bieron 2005 {published data only}
Bieron K, Kostka-Trabka E, Starzyk D, Goszcz A,
Grodzinska L, Korbut R. Bencyclane - A new aspect of the
mechanism of action in patients with peripheral arterial
occlusive disease. Open-label, prospective, randomized
trial. Acta Angiologica 2005;11(3):157–72.
Ciuffetti 1991 {published data only}
Ciuffetti G, Mercuri M, Ott C, Lombardini R, Paltriccia R,
Lupattelli G, et al. Use of pentoxifylline as an inhibitor of
free radical generation in peripheral vascular disease. Results
of a double-blind placebo-controlled study. European
Journal of Clinical Pharmacology 1991;41(6):511–5.
Dawson 1999 {published data only}
Dawson DL, DeMaioribus CA, Hagino RT, Light JT,
Bradley DV Jr, Britt KE, et al. The effect of withdrawal of
drugs treating intermittent claudication. American Journal
of Surgery 1999;178(2):141–6.
Dettori 1989 {published data only}
Dettori AG, Pini M, Moratti A, Paolicelli M, Basevi P,
Quintavalla R, et al. Acenocoumarol and pentoxifylline in
intermittent claudication. A controlled clinical study. The
APIC Study Group. Angiology 1989;40(4 part 1):237–48.
Ehrly 1986 {published data only}
Ehrly AM, Saeger-Lorenz K. Effect of pentoxifylline on
the muscle tissue oxygen pressure of claudicants after
pedoergometric exercise. Angiology. 37 1986; Vol. 37,
issue 5:398.
Ehrly 1987 {published data only}
Ehrly AM, Saeger-Lorenz K. Influence of pentoxifylline
on muscle tissue oxygen tension (pO2) of patients with
intermittent claudication before and after pedal ergometer
exercise. Angiology 1987;38(2 part 1):93–100.
Farkas 1993 {published data only}
Farkas K, Horvath P, Farsang C. Pentoxifylline treatment
of patients with peripheral obstructive vascular disease.
International Angiology. 12 1993; Vol. 12:64.
Fossat 1995 {published data only}
Fossat C, Fabre D, Alimi Y, Bienvenu J, Aillaud MF, Lenoble
M, et al. Leukocyte activation study during occlusive
arterial disease of the lower limb: effect of pentoxifylline
infusion. Journal of Cardiovascular Pharmacology 1995;25
Suppl 2:96–100.
Guest 2005 {published data only}
Guest JF, Davie AM, Clegg JP. Cost effectiveness of
cilostazol compared with naftidrofuryl and pentoxifylline
in the treatment of intermittent claudication in the UK.
Current Medical Research and Opinion 2005;21(6):817–26.
Hepp 1996 {published data only}
Hepp W, Von Bary S, Corovic D, Diehm C, Muhe E,
Rudofsky G, et al. Clinical efficacy of IV prostaglandin
E1 and IV pentoxifylline in patients with arterial occlusive
disease of fontaine stage IIb: a multicenter, randomized
comparative study. International Journal of Angiology 1996;
5(1):32–7.
Horowitz 1982 {published data only}
Horowitz I. Results of a multicenter randomised
double blind study. Pentoxyifylline versus placebo for 6
months on lower limb artertiopathies [Resultats d’une
etude multicentrique randomisee en double aveugle.
Pentoxifylline contre placebo prolongee sur 6 mois dans
les arteriopathies des membres inferieurs]. Actualities
D’Angiologie 1982;7:31–4.
Incandela 2002 {published data only}
Incandela L, De Sanctis MT, Cesarone MR, Belcaro
G, Nicolaides AN, Geroulakos G, et al. Short-range
intermittent claudication and rest pain: microcirculatory
effects of pentoxifylline in a randomized, controlled trial.
Angiology 2002;53 Suppl 1:27–30.
Kellner 1976 {published data only}
Kellner H. Treatment of chronic arterial circulatory
disorders. Double blind trial with Trental 400. MMW,
Munchener Medizinische Wochenschrift 1976;118(43):
1399–402.
Luk’Janov 1995 {published data only}
Luk’Janov Y. Hemorheologic and hemodynamic changes
after treatments with PGE versus pentoxifylline (PF) in
patients with peripheral arterial disease (PAD). International
Angiology. 14 1995; Vol. 14 Suppl 1:372.
Milio 2003 {published data only}
Milio G, Cospite V, Cospite M. Effects of PGE-1 in patients
suffering from peripheral arterial occlusive disease. Minerva
Cardioangiologica 2003;51(3):311–6.
Milio 2006 {published data only}
Milio G, Coppola G, Novo S. The effects of prostaglandin E-
1 in patients with intermittent claudication. Cardiovascular
& Hematological Disorders Drug Targets 2006;6(2):71–6.
Panchenko 1997 {published data only}
Panchenko E, Eshkeeva A, Dobrovolsky A, Titaeva E,
Podinovskaya Y, Hussain KM, et al. Effects of indobufen
and pentoxifylline on walking capacity and hemostasis
in patients with intermittent claudication: results of six
months treatment. Angiology 1997;48(3):247–54.
Pignoli 1985 {published data only}
Pignoli P, Ciccolo F, Villa V, Longo T. Comparative
evaluation of buflomedil and pentoxifylline in patients with
peripheral arterial occlusive disease. Current Therapeutic
Research 1985;37(4):596–606.
Poggesi 1985 {published data only}
Poggesi L, Scarti L, Boddi M, Masotti G, Serneri GG.
Pentoxifylline treatment in patients with occlusive
peripheral arterial disease. Circulatory changes and effects
on prostaglandin synthesis. Angiology 1985;36(9):628–37.
21Pentoxifylline for intermittent claudication (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Regenthal 1991 {published data only}
Regenthal R, Voigt H, Reuter W, Preiss R. The effect
of oral trapidil therapy on clinical and hemorheological
parameters in arteriosclerosis obliterans in comparison to
pentoxifylline - a pilot study [On the influence of the oral
trapidil therapy on clinical and haemorrheologic parameters
in arteriosclerosis obliterans in comparison to pentoxifylline
– a pilot study]. Zeitschrift fur die Gesamte Innere Medizin
und Ihre Grenzgebiete 1991;46(6):185–90.
Reilly 1987 {published data only}
Reilly DT, Quinton DN, Barrie WW. A controlled trial of
pentoxifylline (Trental 400) in intermittent claudication:
clinical, haemostatic and rheological effects. New Zealand
Medical Journal 1987;100(828):445–7.
Rodin 1998 {published data only}
Rodin SM. Pletal (cilostazol) tablets. Center for Drug
Evaluation and Research. Application number: NDA 20-
863,. Study 21–96–202 1998; Vol. Study 21–96–202:
27–40.
Rodin 1998a {published data only}
Rodin SM. Pletal (cilostazol) Tablets. Center for Drug
Evaluation and Research. Application number: NDA 20-
863 Otsuka America,. Study 21–94–301 1998; Vol. Study
21–94–301:58–72.
Roekaerts 1984 {published data only}
Roekaerts F, Deleers L. Trental 400 in the treatment of
intermittent claudication: results of long-term, placebo-
controlled administration. Angiology 1984;35(7):396–406.
Rudofsky 1987 {published data only}
Rudofsky G, Haussler KF, Kunkel HP, Schneider-May H,
Spengel F, Symann O, et al. Effectiveness of intravenous
infusion treatment of peripheral arterial occlusive disease
with Trental - results of a multicenter double-blind study
[Zur wirksamkeit einer intravenosen infusionbehandlung
der peripheren arteriellen verschlubkrankheit mit Trental
– Ergebnisse einer multi–zentrischen doppelblindstudie].
Vasa - Supplementum 1987;20:375–8.
Rudofsky 1988 {published data only}
Rudofsky G, Haussler KF, Kunkel HP, Schneider-May H,
Spengel F, Symann O, et al. Intravenous pentoxifylline
treatment in chronic peripheral arterial disease. Die
Medizinische Welt 1988;39(39):1136–40.
Rudofsky 1989 {published data only}
Rudofsky G, Haussler KF, Kunkel HP, Schneider-May
H, Spengel F, Symann O, et al. Intravenous treatment
of chronic peripheral occlusive arterial disease: a double-
blind, placebo-controlled, randomized, multicenter trial of
pentoxifylline. Angiology 1989;40(7):639–49.
Scheffler 1991 {published data only}
Scheffler P, de la Hamette D, Muller H. [Controlled vascular
training in IIb peripheral arterial occlusive disease: additive
effect of intravenous PGE1 versus intravenous pentoxifylline
during training]. [German]. Vasa - Supplementum 1991;33:
350–2.
Scheffler 1994 {published data only}
Scheffler P, de la Hamette D, Gross J, Mueller H, Schieffer
H. Intensive vascular training in stage IIb of peripheral
arterial occlusive disease. The additive effects of intravenous
prostaglandin E1 or intravenous pentoxifylline during
training. Circulation 1994;90(2):818–22.
Schubotz 1976 {published data only}
Schubotz R. Double-blind trial of pentoxifylline in diabetics
with peripheral vascular disorders. Pharmatherapeutica
1976;1(3):172–9.
Shustov 1997 {published data only}
Shustov SB, Canova N. Controlled clinical trial on the
efficacy and safety of oral sulodexide in patients with
peripheral occlusive arterial disease. Current Medical
Research and Opinion 1997;13(10):573–82.
Singh 2009 {published data only}
Singh S, Singh H, Kohli A, Kapoor V, Singh G. Effects of
cilostazole and pentoxifylline on claudication distance and
lipid profile in patients with occlusive peripheral arterial
disease: a comparative trial. Indian Journal of Thoracic
Cardiovascular Surgery 2009;25:45–8.
Strano 1984 {published data only}
Strano A, Davi G, Avellone G, Novo S, Pinto A. Double-
blind, crossover study of the clinical efficacy and the
hemorheological effects of pentoxifylline in patients with
occlusive arterial disease of the lower limbs. Angiology 1984;
35(7):459–66.
Strano 2002 {published data only}
Strano A. Propionyl-L-carnitine versus pentoxifylline:
improvement in walking capacity in patients with
intermittent claudication. Clinical Drug Investigation 2002;
22 Suppl 1:1–6.
Thomson 1990 {published data only}
Thomson GJ, Thomson S, Todd AS, Vohra RK, Carr MH,
Walker MG. Combined intravenous and oral pentoxifylline
in the treatment of peripheral vascular disease. A clinical
trial. International Angiology 1990;9(4):266–70.
Tonak 1977 {published data only}
Tonak J, Knecht H, Groitl H. Treatment of circulation
disorders with pentoxifylline. A double-blind study with
Trental [Zur behandlung von durchblutungsstorungen
mit pentoxifyllin. Eine doppelblindstudie mit trental].
Medizinische Monatsschrift 1977;31(10):467–72.
Triebe 1992 {published data only}
Triebe G, Munnich U, Liebold F. [A therapeutic comparison
between hemodilution and pentoxifylline in arterial
obstructive disease. An objective assessment by quantitative
Doppler sonography]. [German]. Deutsche Medizinische
Wochenschrift 1992;117(14):523–30.
Tsang 1994 {published data only}
Tsang GM, Sanghera K, Gosling P, Smith FC, Paterson
IS, Simms MH, et al. Pharmacological reduction of the
systemically damaging effects of local ischaemia. European
Journal of Vascular Surgery 1994;8(2):205–8.
22Pentoxifylline for intermittent claudication (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wang 2003 {published data only}
Wang T, Elam MB, Forbes WP, Zhong J, Nakajima K.
Reduction of remnant lipoprotein cholesterol concentrations
by cilostazol in patients with intermittent claudication.
Atherosclerosis 2003;171(2):337–42.
Additional references
Bachoo 2010
Bachoo P, Thorpe PA, Maxwell H, Welch K. Endovascular
stents for intermittent claudication. Cochrane Database
of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/
14651858.CD003228.pub2]
Bedenis 2014
Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis
DP, Stansby G. Cilostazol for intermittent claudication.
Cochrane Database of Systematic Reviews 2014, Issue 10.
[DOI: 10.1002/14651858.CD003748.pub4]
Dawson 2002
Dawson DL, Zheng Q, Worthy SA, Charles B, Bradley
DV Jr. Failure of pentoxifylline or cilostazol to improve
blood and plasma viscosity, fibrinogen, and erythrocyte
deformability in claudication. Angiology 2002;53(5):
509–20.
de Backer 2012
de Backer TLM, Vander Stichele R, Lehert P, Van Bortel
L. Naftidrofuryl for intermittent claudication. Cochrane
Database of Systematic Reviews 2012, Issue 12. [DOI:
10.1002/14651858.CD001368.pub4]
de Backer 2013
de Backer TLM, Vander Stichele R. Buflomedil
for intermittent claudication. Cochrane Database of
Systematic Reviews 2013, Issue 3. [DOI: 10.1002/
14651858.CD000988.pub4]
Ernst 1994
Ernst E. Pentoxifylline for intermittent claudication. A
critical review. Angiology 1994;45(5):339–45.
Fontaine 1954
Fontaine VR, Kim M, Kieny R. Surgical treatment
of peripheral circulation disorders [Die chirurgische
Behandlung der peripheren Durchblutungsstörungen].
Helvetica Chirurgica Acta 1954;21(5-6):499–533.
Fowkes 1998
Fowkes G, Gillespie IN. Angioplasty (versus non surgical
management) for intermittent claudication. Cochrane
Database of Systematic Reviews 1998, Issue 2. [DOI:
10.1002/14651858.CD000017]
Fowkes 2013
Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg
JO, McDermott MM, et al. Comparison of global estimates
of prevalence and risk factors for peripheral artery disease in
2000 and 2010: a systematic review and analysis. Lancet
2013;382(9901):1329–40.
Frampton 1995
Frampton JE, Brogden RN. Pentoxifylline (oxpentifylline).
A review of its therapeutic efficacy in the management of
peripheral vascular and cerebrovascular disorders. Drugs &
Aging 1995;7(6):480–503.
Gillings 1987
Gillings D, Koch G, Reich T, Stager WJ. Another look at
the pentoxifylline efficacy data for intermittent claudication.
Journal of Clinical Pharmacology 1987;27(8):601–9.
Higgins 2011
Higgins JPT, Green S, editors. Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 [updated
March 2011]. The Cochrane Collaboration, 2011.
Available from www.cochrane-handbook.org.
Lane 2014
Lane R, Ellis B, Watson L, Leng GC. Exercise for
intermittent claudication. Cochrane Database of
Systematic Reviews 2014, Issue 7. [DOI: 10.1002/
14651858.CD000990.pub3]
Lee 2001a
Lee TM, Su SF, Hwang JJ, Tseng CD, Chen MF, Lee
YT, et al. Differential lipogenic effects of cilostazol and
pentoxifylline in patients with intermittent claudication:
potential role for interleukin-6. Atherosclerosis 2001;158(2):
471–6.
Meijer 2002
Meijer WT, Cost B, Bernsen RM, Hoes AW. Incidence and
management of intermittent claudication in primary care in
The Netherlands. Scandinavian Journal of Primary Health
Care 2002;20(1):33–4.
Meng 2014
Meng Y, Squires H, Stevens JW, Simpson E, Harnan
S, Thomas S, et al. Cost-effectiveness of cilostazol,
naftidrofuryl oxalate, and pentoxifylline for the treatment of
intermittent claudication in people with peripheral arterial
disease. Angiology 2014;65(3):190–7.
Micromedex 2002
MICROMEDEX, Englewood, Colorado (Edition expires
[12/2002]). MICROMEDEX® Healthcare Series. http://
lrs.lendac.ie/m&p.html.
Moher 2000
Moher D, Pham B, AusejoM, Saenz A, Hood S, Barber GG.
Pharmacological management of intermittent claudication:
a meta-analysis of randomised trials. Drugs 2000;59(5):
1057–70.
NICE 2011
National Institute for Health and Care Excellence (NICE).
Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol
nicotinate for the treatment of intermittent claudication in
people with peripheral arterial disease. www.nice.org.uk/
guidance/TA223/chapter/2-Clinical-need-and-practice
(accessed 5 April 2015).
NICE 2012
National Institute for Health and Care Excellence
(NICE). Lower limb peripheral arterial disease: diagnosis
and management. www.nice.org.uk/Guidance/CG147
(accessed 5 April 2015).
23Pentoxifylline for intermittent claudication (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Reich 1984
Reich T, Cutler BC, Lee BY, Porter JM, Reichle FA, Scogin
JT, et al. Pentoxifylline in the treatment of intermittent
claudication of the lower limbs. Angiology 1984;35(7):
389–95.
Robertson 2013
Robertson L, Andras A. Prostanoids for intermittent
claudication. Cochrane Database of Systematic Reviews 2013,
Issue 4. [DOI: 10.1002/14651858.CD000986.pub3]
Squires 2010
Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong
R. Cilostazol, naftidrofuryl oxalate, pentoxifylline and
inositol nicotinate for intermittent claudication in people
with peripheral arterial disease. Technology Assessment
Report commissioned by the NIHR HTA Programme on
behalf of the National Institute for Health and Clinical
Excellence 2010.
Squires 2011
Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong
R, et al. A systematic review and economic evaluation of
cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol
nicotinate for the treatment of intermittent claudication in
people with peripheral arterial disease. Health Technology
Assessment 2011;15(40):1–210.
Stevens 2012
Stevens JW, Simpson E, Harnan S, Squires H, Meng
Y, Thomas S, et al. Systematic review of the efficacy of
cilostazol, naftidrofuryl oxalate and pentoxifylline for the
treatment of intermittent claudication. British Journal of
Surgery 2012;99(12):1630–8.
Tendera 2011
Tendera M, Aboyans V, Bartelink M-L, Baumgartner I,
Clement D, Collet J-P, et al. ESC Guidelines on the
diagnosis and treatment of peripheral artery diseases.
European Heart Journal 2011;32:2851–906.
Wong 2011
Wong PF, Chong LY, Mikhailidis DP, Robless P, Stansby G.
Antiplatelet agents for intermittent claudication. Cochrane
Database of Systematic Reviews 2011, Issue 11. [DOI:
10.1002/14651858.CD001272]
References to other published versions of this review
Salhiyyah 2005
Salhiyyah K, Palfreyman SSJ, Booth A, Michaels JA,
Senanayake E. Pentoxifylline for intermittent claudication.
Cochrane Database of Systematic Reviews 2005, Issue 2.
[DOI: 10.1002/14651858.CD005262]
Salhiyyah 2012
Salhiyyah K, Senanayake E, Abdel-Hadi M, Booth A,
Michaels JA. Pentoxifylline for intermittent claudication.
Cochrane Database of Systematic Reviews 2012, Issue 1.
[DOI: 10.1002/14651858.CD005262.pub2]
∗ Indicates the major publication for the study
24Pentoxifylline for intermittent claudication (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Accetto 1982
Methods Study design: double-blinded, randomised
Country: Yugoslavia
Setting: single centre
Intention-to-treat: no
Participants Number of participants randomly assigned: 60
Number of participants analysed: 47 (23 pentoxifylline, 24 nylidrin HCL)
Exclusions post randomisation: 13
Losses to follow-up: none
Age: mean 61 years (range 30 to 80 years)
Sex: 36 male, 14 female
Inclusion criteria: Fontaine stage II or III; initial claudication distance > 50 m and < 500
m at 3 km/h at 0 degrees of inclination; severity of disorder unchanged for 6 months
Exclusion criteria: advanced limb arterial occlusion; peripheral venous disorders; sys-
temic haematological disorders; severely impaired renal function; GI disorders; hyper-
sensitivities to methylxanthines; women of childbearing age; taking cardiac medication,
glycosides and antihypertensives or antibiotics < 4 weeks before the study
Interventions Treatment: oral pentoxifylline, 400 mg 3 times daily
Control: nylidrin HCl, 3 mg 3 times daily
Duration: 8 weeks
Outcomes Primary: mean TWD
Secondary: side effects
Notes Treadmill protocol: 3 km/h without inclination
Mean TWD stated in metres and seconds
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not mentioned
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Reports ’double blinded’; no other infor-
mation available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
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Accetto 1982 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Reasons for withdrawals not provided
Selective reporting (reporting bias) Unclear risk Protocol not available; insufficient infor-
mation available to permit judgement
Other bias Low risk Study appears free of other bias
Belcaro 2002
Methods Study design: double-blinded, randomised
Country: Italy/USA/UK
Setting: 3 centres
Intention-to-treat: no
Participants Number of participants randomly assigned: 60
Number of participants analysed: 53 (27 pentoxifylline, 26 placebo)
Exclusions post randomisation: 7
Losses to follow-up: none
Age: pentoxifylline: 55 ± 7 years, placebo: 56 ± 11 years
Sex: M:F: pentoxifylline: 16:11, placebo: 18:8
Inclusion criteria: severe intermittent claudication with total walking distance < 100
m; intermittent claudication > 3 months; resting Doppler ankle brachial index < 0.8;
decrease in ankle pressure > 15 mmHg after standard exercise test on treadmill;
age between 45 and 75 years; arterial stenoses, plaques and blood flow reduction due to
arteriosclerosis (colour duplex); graded cardiac stress test showing no angina/MI; stable
control of diabetes mellitus ≥ 5 years
Exclusion criteria: presence of indication for vascular angioplasty or revascularisation;
angina or cardiac ischaemia on effort; previous coronary or vascular surgery or angio-
plasty, aneurysm, congestive heart failure, renal failure (creatinine > 2 mg/dL) and di-
abetes requiring insulin; arthritis, pulmonary, cardiac, neoplastic inflammatory or im-
munologic disease
Exclusion criteria after run-in phase: variance of maximal walking distance > 25% during
2-week run-in phase
Interventions Treatment: oral pentoxifylline, 400 mg 4 times daily
Control: placebo
Duration: 6 months
Outcomes Primary: mean TWD
Secondary: side effects
Notes Treadmill protocol: 3 km/h at 12% inclination
Mean TWD expressed in metres only
Risk of bias
Bias Authors’ judgement Support for judgement
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Belcaro 2002 (Continued)
Random sequence generation (selection
bias)
Unclear risk States ’randomized’; no other information
available
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Treatment allocation blinded for partici-
pants and personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk Protocol not available; insufficient infor-
mation available to permit judgement
Other bias Low risk Study appears free of other bias
Bohmer 1988
Methods Study design: double-blinded, randomised
Country: Germany
Setting: single centre
Intention-to-treat: not mentioned
Participants Number of participants randomly assigned: 27 (14 Ginkgo biloba extract, 13 pentoxi-
fylline)
Number of participants analysed: 26
Exclusions post randomisation: none
Losses to follow-up: 1
Age: 60.3 ± 7.3 years (range 44 to 72 years)
Sex: 24 males, 3 females
Inclusion criteria: outpatient; high-grade stenosis for SFA; 1-side claudication; PFWD
50 to 200 m;
< 30% variance in WD during 3-week placebo induction phase
Exclusion criteria: not mentioned
Interventions Treatment: pentoxifylline, 1200 mg/d
Control: Ginkgo biloba extract, 160 mg/d
Duration: 24 weeks
Outcomes Primary: mean PFWD, TWD
Secondary: ABI
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Bohmer 1988 (Continued)
Notes Treadmill protocol: 3 km/h at 5% inclination
Mean PFWD and TWD expressed in metres only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States ’randomised’; no other information
provided
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Reports ’double blind’; no other informa-
tion available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk Protocol not available; insufficient infor-
mation available to permit judgement
Other bias Low risk Study appears free of other bias
Bollinger 1977
Methods Study design: double-blinded, randomised
Country: Switzerland
Setting: single centre
Intention-to-treat: not mentioned
Participants Number of participants randomly assigned: 26
Number of participants analysed: 19
Exclusions post randomisation: none
Losses to follow-up: 7
Age: pentoxifylline: mean 63.9 years, placebo: mean 59.6 years
Sex: pentoxifylline: 9 male, 1 female, placebo: 8 male, 1 female
Inclusion criteria: intermittent claudication (Fontaine stage II)
Exclusion criteria: malleolar arteries could not be compressed by a cuff (mediasclerosis)
Interventions Treatment: oral pentoxifylline, 200 mg 3 times daily
Control: placebo
Duration: 8 weeks
28Pentoxifylline for intermittent claudication (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bollinger 1977 (Continued)
Outcomes Primary: mean TWD
Secondary: ABI
Notes Treadmill protocol: 3.2 km/h at 12.5% inclination
Mean TWD expressed in metres only
Participants were instructed to refrain from smoking during the study and to walk daily
for at least 1 hour
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States ’allocated at random to receive treat-
ments’; no other information provided
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Both pentoxifylline and placebo were pre-
sented in identical tablet form and supplied
in containers of 40 tablets, identified only
by a code number’
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk Protocol not available; insufficient infor-
mation available to permit judgement
Other bias High risk Differences in clinical baseline data be-
tween treatment groups
Cesarone 2002b
Methods Study design: double-blinded, randomised
Country: Italy
Setting: multi-centre - 7 centres
Intention-to-treat: yes
Participants Number of participants randomly assigned: 200
Number of participants analysed: 178 (88 pentoxifylline, 90 placebo)
Exclusions post randomisation: none
Losses to follow-up: 22
Age: pentoxifylline: 61 ± 9 years, placebo: 61 ± 10 years
Sex: pentoxifylline: 55 males, 45 females, placebo: 56 males, 44 females
29Pentoxifylline for intermittent claudication (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cesarone 2002b (Continued)
Inclusion criteria: severe intermittent claudication with total walking distance between
50 and 200 m; intermittent claudication > 4 months; resting Doppler ankle-brachial
index < 0.8; decrease in ankle pressure > 15 mmHg after standard exercise rest on
treadmill (12% inclination, 3 km/h, 10minutes of exercise); age between 45 and 75 years;
documentation of arterial stenoses, plaques and flow reduction due to arteriosclerosis by
colour-duplex imaging
Exclusion criteria: indication for revascularisation or angioplasty; no angina or myocar-
dial ischaemia on effort tested by bicycle ergometry, cardiac risk factors; previous coro-
nary or vascular surgery or angioplasty; aneurysms; congestive heart failure NYHA III/
IV; renal failure (creatinine > 2mg/100mL); insulin-dependent diabetesmellitus; change
of > ± 25% during 2-week run-in period; arthritis; pulmonary, cardiac or neoplastic
disease; inflammatory or immunologic disease
Interventions Treatment: oral pentoxifylline, 400 mg 4 times daily
Control: placebo
Duration: 40 weeks
Outcomes Primary: geometric mean TWD and PFWD
Secondary: side effects
Notes Treadmill protocol: 3 km/h at 12% inclination
Geometric mean PFWD and TWD expressed in metres only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States ’randomised into two treatment
plans’; no further information provided
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk States ’double blind’ and ’pentoxifylline
and equivalent placebo were administered’;
no other information provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information provided on dropouts
Selective reporting (reporting bias) Unclear risk Protocol not available; insufficient infor-
mation available to permit judgement
Other bias Low risk Study appears free of other bias
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Chacon-Quevedo 1994
Methods Study design: double-blinded, randomised
Country: Spain
Setting: single centre
Intention-to-treat: not mentioned
Participants Number of participants randomly assigned: 45 (15 in each arm)
Number of participants analysed: 45
Exclusions post randomisation: none
Losses to follow-up: none
Age: 61 ± 8 years
Sex: all men
Inclusion criteria: PAD Fontaine stage II
Exclusion criteria: not mentioned
Interventions Treatment: pentoxifylline, 1200 mg/d
Control:
• Buflomedil, 600 mg/d
• Nifedipine, 600 mg/d
Duration: 90 days
Outcomes Primary: mean PFWD, TWD
Secondary: ABI
Notes Treadmill protocol: 3 km/h at 10% inclination
Mean PFWD and TWD expressed in metres only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States ’patients were divided randomly into
three treatment groups’; no other informa-
tion provided
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information provided to per-
mit judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Insufficient information provided to per-
mit judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk Insufficient information provided to per-
mit judgement
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Chacon-Quevedo 1994 (Continued)
Other bias Unclear risk Insufficient information provided to per-
mit judgement
Ciocon 1997
Methods Study design: randomised
Country: USA
Setting: 2 centres
Intention-to-treat: not mentioned
Participants Number of participants randomly assigned: 90
Number of participants analysed: 90 (45 in each group)
Exclusions post randomisation: not mentioned
Losses to follow-up: not mentioned
Age: 79 ± 3.5 years
Sex: M:F: pentoxifylline: 10:34, aspirin: 12:34
Inclusion criteria: age ≥ 65 years; ankle-to-arm pressure < 0.8; not taken aspirin/pen-
toxifylline over previous 6 months; experienced leg claudication
Exclusion criteria: took aspirin or pentoxifylline in previous 6 months; leg rest pain;
vascular surgery; co-existing stable angina, severe osteoarthritis, peripheral neuropathy,
leg surgery within previous 6 months; ankle-to-arm pressure ratio > 0.8
Interventions Treatment: oral pentoxifylline, 400 mg twice daily
Control: aspirin, 325 mg daily
Duration: 6 weeks
Outcomes Primary: TWD
Secondary: ABI
Notes Treadmill protocol: not specified
TWD expressed in metres only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States ’were randomly assigned to’; no fur-
ther information provided
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Different treatments: pentoxifylline twice
daily, aspirin once daily
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
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Ciocon 1997 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Unclear risk Protocol not available; insufficient infor-
mation available to permit judgement
Other bias Low risk Study appears free of other bias
Creager 2008
Methods Study design: double-blinded, randomised
Country: USA
Setting: 32 centres
Intention-to-treat: not mentioned: yes
Participants Number of participants randomly assigned: 430
Number of participants analysed: 370
Exclusions post randomisation: none
Losses to follow-up: 60
Age: 67 years
Sex: M:F: 349:81
Inclusion criteria: age ≥ 40 years; Fontaine stage II; stable claudication for ≥ 3 months
despite standard care; absolute claudication distance between 50 and 800 m; ABPI ≤
0.90 in symptomatic leg and > 20% fall in ABPI within 1 minute following cessation
of exercise; in non-compressible vessels, toe-brachial index at rest < 0.70; final inclusion
criteria after run-in phase: absolute claudicationdistancewithin 20%ofACDonprevious
measurements before run-in phase; compliance with drug of 80% to 120%
Exclusion criteria: ischaemic rest pain, ulcers, gangrene (Fontaine stage III and IV); ev-
idence of non-atherosclerotic PAD; peripheral neuropathy impairing walking; revascu-
larisation procedures within preceding 3months; sympathectomy within 6months; type
1 diabetes mellitus; myocardial infarction or major cardiac surgery within 3 months;
unstable angina; heart failure; patients receiving low molecular weight heparin and war-
farin in combination with aspirin, or any other drug for intermittent claudication
Interventions Treatment: oral pentoxifylline, 400 mg 3 times daily
Control
• Placebo
• Iloprost 50 µg bd
• Iloprost 100 µg bd
• Iloprost 150 µg bd
Duration: 6 months
Outcomes Primary: TWD expressed as % change from baseline to follow-up
Secondary: PFWD, quality of life (WIQ and SF36), side effects
Notes Treadmill protocol: 3.2 km/h at 0% gradient, increased by 2% every 2 minutes
TWD expressed in metres at baseline and % change at follow-up
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Creager 2008 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States ’randomised placebo controlled’; no
further information provided
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Treatments appropriately blinded for par-
ticipants and personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear why participants stopped medica-
tion; unclear whether data presented rep-
resent intention-to-treat or per-protocol
analysis
Selective reporting (reporting bias) Unclear risk Insufficient information to permit judge-
ment
Other bias Unclear risk Sponsor: Berlex Pharmaceuticals Inc.
Dawson 2000
Methods Study design: double-blinded, randomised
Country: USA
Setting: multi-centre - 54 centres
Intention-to-treat: yes
Participants Number of participants randomly assigned: 699
Number of participants analysed: 698
Exclusions post randomisation: 1
Losses to follow-up: 159
Age: 66 ± 9 years for all groups
Sex: cilostazol: 172 male, pentoxifylline: 181 male, placebo: 176 male
Inclusion criteria: > 6 months of symptoms with no substantial change within previous
3 months; baseline claudication distance > 53.6 m (1 minute on treadmill protocol)
; baseline walking distance < 537.6 m (10 minutes on treadmill protocol); peripheral
arterial disease diagnosis confirmed by either a resting ABI ≤ 0.9 and a ≥ 10 mmHg
decrease in ankle pressure measured 1 minute after walking to maximal walking distance
or a ≥ 20 mmHg decrease in post-exercise ankle pressure in symptomatic extremity
Exclusion criteria: Buerger’s disease; critical ischaemia (II or III chronic lower extremity
ischaemia); lower extremity arterial reconstruction (surgical or endovascular) or sympa-
34Pentoxifylline for intermittent claudication (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dawson 2000 (Continued)
thectomy within previous 3 months; other conditions limiting exercise capacity; other
medical conditions limiting participation; prior use of cilostazol or pentoxifylline within
30 days of start date; > 20% variation in maximal walking distance; use of anticoagulants
or antiplatelet agents except for aspirin at a dose ≤ 81 mg/d
Interventions Treatment: oral pentoxifylline, 400 mg 3 times daily
Control
• Placebo
• Cilostazol, 100 mg twice daily plus 1 identical placebo tablet
Duration: 24 weeks
Outcomes Primary: mean PFWD, TWD
Secondary: ABI, side effects and QoL (SF36, WIQ)
Notes Treadmill protocol: 3.2 km/h at 0% inclination, increased by 3.5% every 3 minutes
Mean PFWD and TWD expressed in metres only
Additional data on a subgroup of this study are presented in Dawson 2002
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified by clinical centre and patients as-
signed to 1 of 3 treatment regimes within
each centre using permuted block design
Allocation concealment (selection bias) Low risk ’Interactive voice randomization that
blinded the investigator, patients and spon-
sor from treatment assignment’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Treatments appropriately blinded for par-
ticipants and personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Unclear risk Protocol not available; insufficient infor-
mation available to permit judgement
Other bias Unclear risk ’Supported by Otsuka America Pharma-
ceuticals Inc., a US affiliate of the manu-
facturer of cilostazol’
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De Sanctis 2002a
Methods Study design: double-blinded, randomised
Country: USA
Setting: 5 centres
Intention-to-treat: yes
Participants Number of participants randomly assigned: 120
Number of participants analysed: 101 (56 pentoxifylline, 45 placebo)
Exclusions post randomisation: 19
Losses to follow-up: none
Age: pentoxifylline: 63 ± 4 years, placebo: 62 ± 3 years
Sex: M:F: pentoxifylline: 36:20, placebo: 24:21
Inclusion criteria: severe intermittent claudicationwith total walking distance between50
and 200 m; intermittent claudication > 4 months; resting Doppler ankle-brachial index
< 0.8; decrease in ankle pressure > 15 mmHg after standard exercise test on treadmill; age
between 45 and 75 years; documentation of arterial stenoses, plaques and flow reduction
due to arteriosclerosis by colour-duplex imaging
Exclusion criteria: presence of indication for revascularisation or angioplasty procedures;
angina pectoris or myocardial ischaemia on effort at 80% of target heart rate; previous
coronary or vascular surgery or angioplasty; aneurysms, congestive heart failure NYHA
III-IV, renal failure (creatinine > 2 mg/dL), IDDM II; change > ± 25% during 2-week
run in period; arthritis or other pulmonary, cardiac or neoplastic disease or inflammatory
or immunologic disease
Interventions Treatment: oral pentoxifylline, 600 mg 3 times daily
Control: placebo
Duration: 12 months
Outcomes Primary: mean TWD
Secondary: none
Notes Treadmill protocol: 3 km/h at 12% inclination
Mean TWD expressed in metres only
Participants also took 300 mg antiplatelets as part of study treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States ’patients were randomised into two
treatment plans’; no other informationpro-
vided
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information provided to per-
mit judgement
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De Sanctis 2002a (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information on dropouts provided
other than due to low compliance
Selective reporting (reporting bias) Unclear risk No information on dropouts provided
other than due to low compliance
Other bias Unclear risk Pentoxifylline dose unclear; study authors
report both 1600 mg and 1800 mg. As-
sumed 1800 mg (3 × 600 mg) is actual
treatment
De Sanctis 2002b
Methods Study design: double-blinded, randomised
Country: USA
Setting: 5 centres
Intention-to-treat: no
Participants Number of participants randomly assigned: 194
Number of participants analysed: 135 (75 pentoxifylline, 60 placebo)
Exclusions post randomisation: 59
Losses to follow-up: none
Age: pentoxifylline: 62 ± 9 years, placebo: 61 ± 8 years
Sex: M:F: pentoxifylline: 46:29, placebo: 28:22
Inclusion criteria: intermittent claudication with total walking distance > 400 m; claudi-
cation > 3 months; Doppler ankle-brachial index < 0.8; decrease in ankle pressure > 20
mm Hg after standard exercise test on treadmill; age between 50 and 65 years; arterial
stenoses, plaques and flow reduction on colour duplex imaging
Exclusion criteria: presence of Indication for revascularisation or angioplasty; angina or
myocardial ischaemia on effort; previous coronary or vascular surgery or angioplasty,
aneurysms, congestive heart failure NYHA III/IV, renal failure (creatinine > 2 mg/dL)
, IDDM II; arthritis; other pulmonary cardiac neoplastic disease or inflammatory or
immunologic disease
Interventions Treatment: oral pentoxifylline, 600 mg 3 times daily
Control: placebo
Duration: 12 months
Outcomes Primary: mean TWD
Secondary: side effects
Notes Treadmill protocol: 3 km/h at 12% inclination
Mean TWD expressed in metres only
Participants also took 300 mg antiplatelets as part of study treatment
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De Sanctis 2002b (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States ’patients were randomised into two
treatment plans’; no other informationpro-
vided
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information provided to per-
mit judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information on dropouts provided
other than due to low compliance
Selective reporting (reporting bias) Unclear risk No information on dropouts provided
other than due to low compliance
Other bias Unclear risk Pentoxifylline dose unclear; study authors
report both 1600 mg and 1800 mg. As-
sumed 1800 mg (3 × 600 mg) is actual
treatment
Di Perri 1983
Methods Study design: double-blinded, randomised. Cross-over after 8 weeks
Country: Italy
Setting: single centre
Intention-to-treat: not mentioned
Participants Number of participants randomly assigned: 24
Number of participants analysed: 24
Exclusions post randomisation: none
Losses to follow-up: none
Age: 59.3 years in both groups (range 40 to 71 years)
Sex: group 1: 9 males, 3 females, group 2: 10 males, 2 females
Inclusion criteria: walking capacity between 100 and 400 m; Fontaine II
Exclusion criteria: pain at rest, paraesthesia and skin lesions; diabetes mellitus; severe
hypertension; congestive heart failure
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Di Perri 1983 (Continued)
Interventions Treatment: oral pentoxifylline, 400 mg twice daily
Control: placebo
Duration: 8 weeks and cross-over after 2-week washout phase
Outcomes Primary: mean TWD
Secondary: none
Notes Treadmill protocol: 120 steps/min at horizontal level
Mean TWD expressed in metres only
Participants stopped smoking at the start of the study
Study authors reported a carryover effect that was not eliminated by the washout phase
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States ’randomly allotted into two groups
to received either treatment A or treatment
B’; no other information provided
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Pentoxifylline and placebowere of identical
appearance and were provided as 1 tablet 3
times a day for each treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Adverse events reported only in the sum-
mary, not in the main paper
Selective reporting (reporting bias) Unclear risk Adverse events reported only in the sum-
mary, not in the main paper
Other bias Unclear risk Authors reported a carryover effect that was
not eliminated by the washout phase
Donaldson 1984
Methods Study design: double-blinded, randomised
Country: UK
Setting: single centre
Intention-to-treat: not mentioned
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Donaldson 1984 (Continued)
Participants Number of participants randomly assigned: 80 (40 each arm)
Number of participants analysed: not mentioned
Exclusions post randomisation: none
Losses to follow-up: 7
Age: pentoxifylline: 58.2 ± 11.7 years, placebo: 58.9 ± 9.1 years
Sex: 31 males, 9 females in each group
Inclusion criteria: typical intermittent claudication pain
Exclusion criteria: rest pain (or incipient gangrene); severe ischaemic heart disease; pos-
tural hypotension; receiving any drugs likely to alter claudication distance within 4weeks
before inclusion in the study
Interventions Treatment: oral pentoxifylline, 200 mg 3 times daily
Control: placebo
Duration: 8 weeks
Outcomes Primary: mean PFWD, TWD
Secondary: ABI, side effects
Notes Treadmill protocol: 4 km/h at 0% inclination
Mean PFWD and TWD expressed in metres only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States ’randomised’; no other information
provided
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information provided to per-
mit judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk Protocol not available; insufficient infor-
mation available to permit judgement
Other bias Low risk Study appears free of other bias
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Ernst 1992
Methods Study design: RCT
Country: Austria, Hungary, Germany
Setting: 3 centres
Intention-to-treat: not mentioned
Participants Number of participants randomly assigned: 40 (20 each arm)
Number of participants analysed: 40
Exclusions post randomisation: none
Losses to follow-up: none
Age: pentoxifylline: 53.3 ± 9.6 years, placebo: 55.9 ± 11.9 years
Sex: M:F: pentoxifylline: 15:5, placebo: 19:1
Inclusion criteria: PAD stage II by clinical diagnosis, doppler pressures and angiography;
pain-free walking distance < 200 m; stable ≥ 3 months
Exclusion criteria: claudication due to non-vascular reasons; pre-treatment with drugs
considered to be “rheologically active”
Interventions Treatment: oral pentoxifylline, 600 mg twice daily
Control: placebo
Duration: 12 weeks
Outcomes Primary: mean TWD and PFWD
Secondary: none
Notes Treadmill protocol: not specified
Mean PFWD and TWD expressed in metres only
Both groups received a supervised exercise programme for 1 hour, twice a week
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States ’randomised’; no other information
provided
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Insufficient information provided to per-
mit judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk Protocol not available; insufficient infor-
mation available to permit judgement
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Ernst 1992 (Continued)
Other bias Low risk Study appears free of other bias
Gallus 1985
Methods Study design: double-blinded, randomised. Cross-over after 8 weeks; no washout period
Country: Australia
Setting: single centre
Intention-to-treat: not mentioned
Participants Number of participants randomly assigned: 47
Number of participants analysed: 38 (19 in each group)
Exclusions post randomisation: 9
Losses to follow-up: none
Age: group A: 68 years, group B: 66 years
Sex: group A: 17 males, 2 females, group B: 14 males, 5 females
Inclusion criteria: stable claudication distance > 6months; presence of peripheral vascular
disease documented through clinical examination by vascular surgeon and supplemented
by angiography or non-invasive testing; age > 50 years; pledge not to change smoking
habits during trial; informed consent
Exclusion criteria: vascular surgery or sympathectomy within previous 6 months; is-
chaemic leg ulcer or rest pain; exercise tolerance limited by conditions other than pe-
ripheral vascular disease; treatment with lipid-lowering or antiplatelet drugs
Interventions Treatment: 400 mg twice daily for 1 week, then 400 mg 3 times daily for 7 weeks
Control: placebo
Duration: 8 weeks, then cross-over for another 8 weeks; no washout phase
Outcomes Primary: geometric mean TWD and PFWD
Secondary: ABI
Notes Treadmill protocol: 4 km/h at 10% inclination
Geometric mean PFWD and TWD expressed in metres only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’A random number sequence was used to
form the two treatment groups’
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel blinded from al-
location and held by hospital pharmacy
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Gallus 1985 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ’Results were withheld from investigators
during the study’
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk Protocol not available; insufficient infor-
mation available to permit judgement
Other bias Low risk Study appears free of other bias
Hepp 1992
Methods Study design: double-blinded, randomised
Country: Germany
Setting: 9 centres
Intention-to-treat: not mentioned
Participants Number of participants randomly assigned: 195 (98 pentoxifylline, 97 PGE1)
Number of participants analysed: 195
Exclusions post randomisation: none
Losses to follow-up: none
Age: 65 years
Sex: M:F: 2.8:1
Inclusion criteria: pain-free walking distance 50 to 200m; stable stadiumFontaine IIb for
6months; diagnosis of stenosis through digital substraction angiography or conventional
angiography of lower limbs; signing an informed consent form; variance of walking
distance at beginning < 20%
Exclusion criteria: pregnancy; present heart failure; kidney failure; pre-stenosis (e.g.
stenosis of the aorta abdominalis or iliacal arteries); necrosis or rest pain; pulmonary
insufficiency; arthrosis; myocardial infarction within previous 6 months; orthostatic dys-
regulation and collapsing patients; severe cardiac rhythm problems; epilepsy
Interventions Treatment: intravenous pentoxifylline, 200 mg twice daily
Control: intravenous PGE1, 400 mg twice daily
Duration: 4 weeks
Outcomes Primary: mean TWD and PFWD
Secondary: side effects
Notes Treadmill protocol: not specified
Mean PFWD and TWD expressed in metres only
Risk of bias
Bias Authors’ judgement Support for judgement
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Hepp 1992 (Continued)
Random sequence generation (selection
bias)
Unclear risk States ’randomisation list’; no other infor-
mation provided
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Reports ’blind’, but no other information
provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk Protocol not available; insufficient infor-
mation available to permit judgement
Other bias Low risk Study appears free of other bias
Kiesewetter 1988
Methods Study design: double-blinded, randomised
Country: Germany
Setting: single centre
Intention-to-treat: not mentioned
Participants Number of participants randomly assigned: 40 (20 in each arm)
Number of participants analysed: 38
Exclusions post randomisation: 2
Losses to follow-up: none
Age: pentoxifylline: 59.4 ± 11.4 years, placebo 62.1 ± 8.2 years
Sex: 11 males, 8 females in each group
Inclusion criteria: Fontaine II; already trained patients; 6 months stadium Fontaine IIb;
all patients finished 3 months of exercise training still max walking distance < 300 m;
max walking distance variation in the last 2 weeks (twice/wk) < 30%
Exclusion criteria: other causes for walking problems (e.g. arthrosis, Parkinson’s disease)
; operative therapy within previous 3 months (sympathectomy, vessel operations); my-
ocardial infarction previous 3 months, also apoplexia; severe internistic diseases (e.g.
heart, kidney or liver disease); polyneuropathy
Interventions Treatment: oral pentoxifylline, 400 mg 3 times daily
Control: placebo
Duration: 8 weeks
Outcomes Primary: mean PFWD
Secondary: none
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Kiesewetter 1988 (Continued)
Notes Treadmill protocol: not specified
Mean PFWD expressed in metres only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States ’randomised list’; no other informa-
tion provided
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Tablets were identical and randomisation
key was not known until end of study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to permit judge-
ment
Selective reporting (reporting bias) High risk TWD result reported in abstract but not
mentioned in remainder as outcome or re-
sult
Other bias Low risk Study appears free of other bias
Lee 2001
Methods Study design: double-blinded, randomised
Country: Taiwan
Setting: single centre
Intention-to-treat: not mentioned
Participants Number of participants randomly assigned: 50
Number of participants analysed: 50
Exclusions post randomisation: none
Losses to follow-up: none
Age: cilostazol: 66 ± 9 years, pentoxifylline: 68 ± 5 years, placebo: 69 ± 6 years
Sex: M:F: cilostazol: 14/3, pentoxifylline: 14/3, placebo: 14/2
Inclusion criteria: > 40 years old; stable PAD for last 3 months; baseline max walking
distance > 30 m and < 200 m; variance < 20% in WMD in the 2 screening tests
Exclusion criteria: Buerger’s disease; category II or III chronic lower limb ischaemia;
arterial surgery/angioplasty or sympathectomy within previous 3 months
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Lee 2001 (Continued)
Interventions Treatment: oral pentoxifylline, 400 mg twice daily
Control
• Oral cilostazol, 100 mg twice daily
• Placebo
Duration: 8 weeks
Outcomes Primary: mean TWD
Secondary: ABI, side effects
Notes Treadmill protocol: 3.2 km/h at 12.5% gradient
Mean TWD expressed in metres only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Randomised code number according to
which sponsor supplied the study drug’
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’Special drug packaging was used to main-
tain the blindness of the treatment code’
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk Protocol not available; insufficient infor-
mation available to permit judgement
Other bias Low risk Study appears free of other bias
Lindgarde 1989
Methods Study design: double-blinded, randomised
Country: Scandinavia
Setting: multi-centre
Intention-to-treat: yes
Participants Number of participants randomly assigned: 150 (76 pentoxifylline, 74 placebo)
Number of participants analysed: 150
Exclusions post randomisation: none
Losses to follow-up: none
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Lindgarde 1989 (Continued)
Age: pentoxifylline: 65 ± 7 years, placebo: 64 ± 8 years
Sex: pentoxifylline: 79% males, placebo: 80% males
Inclusion criteria: ≥ 40 years of age; moderate to severe COAD; initial claudication
distance 50 to 200 m; claudication history > 6 months; variance of walking distance <
35% in the last 2 treadmill tests with baseline walking distance < 100 m; variance of
walking distance < 25% in the last 2 treadmill tests with baseline walking distance 101
to 200 m
Exclusion criteria: complete occlusion of the aortoiliac segment, the femoral bifurcation
or the popliteal artery without angiographically proven distal refilling of the respective
segment; vascular reconstruction of sympathectomy within the past 12 months; periph-
eral neuropathy; Buerger’s disease; marked post-phlebotic syndrome; diabetes; cardiac
failure or severe rhythm disorders;
major infections; abnormal values for platelets; history of xanthine hypersensitivity;
addiction to analgesics; malignant disease
Interventions Treatment: oral pentoxifylline, 400 mg 3 times daily
Control: placebo
Duration: 6 months
Outcomes Primary: geometric means of % change in TWD and PFWD from baseline to follow-
up
Secondary: ABI, side effects
Notes Treadmill protocol: 3.2 km/h at 12.5% inclination
PFWD and TWD expressed as geometric mean of % change
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States ’randomisation stratified by centres’;
no other information provided
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk States ’During the double-blind period and
according to a randomization plan, pentox-
ifylline or matching placebo was adminis-
tered t.i.d.’
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ABI data not provided for themain analysis
Selective reporting (reporting bias) Unclear risk ABI data not provided for themain analysis
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Lindgarde 1989 (Continued)
Other bias Low risk Study appears free of other bias
Perhoniemi 1984
Methods Study design: double-blinded, randomised. Cross-over after 3 months
Country: Finland
Setting: single centre
Intention-to-treat: not mentioned
Participants Number of participants randomly assigned: 35
Number of participants analysed: 31 (17 group 1, 14 group 2)
Exclusions post randomisation: none
Losses to follow-up: 4
Age (mean): 60 years (range 45 to 80 years)
Sex: 25 males, 6 females
Inclusion criteria: typical history and objective symptoms of intermittent claudication;
moderate claudication (IIb); max walking distance < 500 m
Exclusion criteria: gangrene or ulcer of the legs; arterial reconstructive surgery within
6 months; symptomatic heart failure or symptomatic angina pectoris limiting exercise
performance; severe hypertension WHO III
Interventions Treatment: oral pentoxifylline, 400 mg 3 times daily
Control: flunarizine, 5 mg 3 times daily
Duration: 3 months, then cross-over; no washout period
Outcomes Primary: median TWD, PFWD
Secondary: ABI, side effects
Notes Treadmill protocol: 3.6 km/h at 0% inclination; in 3 participants, the speedwas increased
to 5.4 km/h
Median PFWD and TWD expressed in metres at baseline and as % change at follow-up
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk States ’patients were randomized into two
groups according to the system of random-
ized blocks’
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants receivedmedication on a ’dou-
ble-dummy basis’; no other information
provided
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Perhoniemi 1984 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk Protocol not available; insufficient infor-
mation available to permit judgement
Other bias Low risk Study appears free of other bias
Porter 1982a
Methods Study design: double-blinded, randomised
Country: USA
Setting: 7 centres
Intention-to-treat: no
Participants Number of participants randomly assigned: 128 (127 + 1 randomised twice), but data
presented for 124 participants (63 pentoxifylline, 61 placebo)
Number of participants analysed: 82
Exclusions post randomisation: 46
Losses to follow-up: none
Age (mean): pentoxifylline: 62.0 (range 47 to 77) years, placebo: 63.5 (range 45 to 81)
years
Sex: pentoxifylline: 51 males, 12 females, placebo: 50 males, 11 females
Inclusion criteria: IC ≥ 6 months; able to walk on treadmill ≥ 50 m at 1.5 mph; ≤ 510
m in 9.5 minutes at a speed of 2 mph before onset of claudication; stable TWD - within
20% change of each other during run in phase
Exclusion criteria: severe COAD with ischaemic pain at rest, ulceration, gangrene; sym-
pathectomy within previous 6 months; severe peripheral neuropathy; chronic infection;
hypersensitivity to methylxanthines (caffeine, theophylline, theobromine); women of
childbearing potential/pregnant or using oral contraceptives
Interventions Treatment: oral pentoxifylline, started at 600 mg, increased gradually to 1200 mg at 1
month
Control: placebo
Duration: 24 weeks
Outcomes Primary: geometric mean of % change in PFWD, TWD
Secondary: side effects
Notes Treadmill protocol: 1.5 mph at 7% inclination
PFWD and TWD expressed as geometric mean of % change
Reich 1984 presents the same study, and an ITT analysis of this study is reported in
Gillings 1987
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Porter 1982a (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States ’randomization was stratified by
clinic’; no other information provided
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reports the use of visibly identical placebo
capsules
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk Protocol not available; insufficient infor-
mation available to permit judgement
Other bias Low risk Study appears free of other bias
Porter 1982b
Methods Study design: double-blinded, randomised
Country: USA
Setting: single
Intention-to-treat: not mentioned
Participants Number of participants randomly assigned: 26
Number of participants analysed: 22 (11 in each group)
Exclusions post randomisation: 4
Losses to follow-up: none
Age (mean): 64 years in total group
Sex: 20 males, 6 females
Inclusion criteria: minimal walking distance > 50 m and < 200 m; lower extremity
intermittent claudication); able to walk on a treadmill
Exclusion criteria: ischaemic rest pain; ulceration; sympathectomy within 6 months;
severe neuropathy; hypersensitivity to methylxanthines; females of childbearing poten-
tial; concomitant drugs known to have any arterial effect; peripheral vasodilators in the
previous 3 months; variance > 20% in walking distance at the last 2 visits
Interventions Treatment: oral pentoxifylline, 600 mg in first week, 800 mg in second week, 1000 mg
in third week, then 1200 mg/d fourth to 24th week
Control: placebo
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Porter 1982b (Continued)
Duration: 24 weeks
Outcomes Primary: TWD, PFWD
Secondary: side effects
Notes Treadmill protocol: 1.5 mph at 7% inclination
PFWD and TWD expressed in metres only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States ’randomised’; no other information
provided
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk States ’Placebo- and drug-treated patients
received identical-appearing capsules on
the same time schedule’
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk Protocol not available; insufficient infor-
mation available to permit judgement
Other bias Low risk Study appears free of other bias
Schellong 2012
Methods Study design: double-blind, randomised controlled trial; parallel assignment
Country: Germany
Setting: multi-site
Intention-to-treat: yes: participants who received ≥ 1 dose of trial medication and who
had ≥ 1 valid measurement of pain-free walking distance under therapy
Participants Number of participants randomly assigned: 561 (pentoxifylline 285, alprostadil 276)
Number of participants analysed: 541 (pentoxifylline 272, alprostadil 269); completed
study: 458 (pentoxifylline 233, alprostadil 225)
Exclusions post randomisation: 103 (pentoxifylline 52, alprostadil 51)
Losses to follow-up: 4 (pentoxifylline 3, alprostadil 1)
Age (mean ± SD): 66.5 ± 8.7 years (pentoxifylline 66.8 ± 8.8 years, alprostadil 66.3 ± 8.
6 years)
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Schellong 2012 (Continued)
Sex: M/F: 173/368 (pentoxifylline 89/183, alprostadil 84/185)
Inclusion criteria: individuals with peripheral arterial occlusive disease (PAOD) of the
lower extremity in Fontaine stage II; maximum walking distance on the treadmill (12%,
3 km/h) between 30 m and 150m; stable intermittent claudication≥ 6 months standing
with no acute shortening of walking distance over the past 3 months; stenoses or occlu-
sions below femoral bifurcation (above-knee or below-knee type) confirmed by duplex
US or angiography; ankle/brachial index≤ 0.90 with a decrease in systolic ankle pressure
≥ 10% after maximum loading (maximum walking distance on the treadmill at 3 km/
h: 12%); patient physically and mentally capable of participating in the trial; patient age
> 40 years, male and female; patient informed and given ample time and opportunity to
think about her/his participation and provided written informed consent; patient willing
and able to comply with all trial requirements
Exclusion criteria: surgical or other interventional measures performed on affected ex-
tremity and prostaglandin treatment within the 6 months immediately before the trial;
rest pain and necroses; systolic ankle pressure < 50 mmHg; change in maximum walking
distance during 1-week run-in phase > ± 25% of baseline; successful physical walking
training within the 6 months immediately before the trial; inflammatory vascular dis-
ease; polyneuropathy in diabetes mellitus; disease limiting walking distance (arthrosis,
inflammatory disease of the joints, neurological disease, disease of the vertebral column,
cardiopulmonary disease); history of pulmonary oedema; myocardial infarction within
previous 6 months; pregnancy or nursing; known hypersensitivity to any components of
trial medication or comparative drug; renal insufficiency, compensated retention (crea-
tinine > 2.0 mg/dL); severe retinal haemorrhage; massive haemorrhage; known existing
malignant disease; vasoactive concomitant medication (e.g. naftidrofuryl, pentoxifylline,
buflomedil, cilostazol) or other prostaglandins; untreated or uncontrolled hypertension
(systolic blood pressure ≥ 180 mmHg, diastolic blood pressure≥ 110 mmHg); previous
participation in the present trial
Interventions Treatment: alprostadil (prostaglandin E1): 8 weeks total; 4 weeks of daily treatment (1
time daily IV infusion of 3 ampoules (20 µg) prostaglandin E1 in 50 to 250 mL physio-
logical saline solution over 2 hours); 4-week interval treatment period (2 times weekly IV
infusion of 3 ampoules (20 µg) of prostaglandin E1 in 50 to 250 mL physiological saline
solution over 2 hours); received placebo tablets mimicking schedule of pentoxifylline
Control: pentoxifylline: Trental, 8 weeks of 2-times-daily 600 mg tablets; received
placebo infusions of saline mimicking the schedule of alprostadil
Duration: 8 weeks
Outcomes Pain-freewalkingdistance, total walkingdistance, quality of life (PAVK86questionnaire)
, side effects
Notes Treadmill test: 12% grade and 3 km/h
All data were retrieved from the ClinicalTrials.gov website, which offered no actual walk-
ing distances - only ratios - and no statistical analyses. A full report of the study includ-
ing outcomes is currently being worked on by trialists and should provide additional
information on bias issues and outcome data
Risk of bias
Bias Authors’ judgement Support for judgement
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Schellong 2012 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not enough information given to deter-
mine adequate random sequence genera-
tion
Allocation concealment (selection bias) Unclear risk Not enough information given to deter-
mine adequate allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind of participants and investi-
gator using adequate techniques to main-
tain blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors not dis-
cussed in abstract
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomly assigned participants were ac-
counted for, and intention-to-treat analy-
sis included nearly all participants; detailed
table given to describe exclusions and loss
to follow-up, although additional informa-
tion should be provided regarding when
these participants dropped out of the study
Selective reporting (reporting bias) Low risk All initially indicated outcomes were re-
ported
Other bias Unclear risk Authors of the study reported that limi-
tations of the study include early termi-
nation, leading to small numbers of par-
ticipants analysed, and technical problems
with measurement, leading to unreliable or
uninterpretable data
Although the work is sponsored by UCB
Pharma, it has been indicated that the PI
of the study is not employed by the spon-
sor, and that the sponsor cannot change
communications or publications about the
project
Volker 1978
Methods Study design: double-blinded, randomised
Country: Germany
Setting: single centre
Intention-to-treat: yes
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Volker 1978 (Continued)
Participants Number of participants randomly assigned: 50 (25 in each arm)
Number of participants analysed: 50
Exclusions post randomisation: none
Losses to follow-up: none
Age: range 56 to 65 years
Sex: pentoxifylline: 18 males, 7 females, placebo: 17 males, 8 females
Inclusion criteria: Fontaine stage II, walking distance < 600 m; no vasoactive substances
allowed
Exclusion criteria: none reported
Interventions Treatment: oral pentoxifylline, 400 mg 3 times daily
Control: placebo
Duration: 4 weeks
Outcomes Primary: mean PFWD
Secondary: quality of life, side effects
Notes Treadmill protocol: not specified
Mean PFWD expressed in metres only
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned according to admission
into the study; no other information pro-
vided
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Reported ’double-blind’; no other informa-
tion provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk No incomplete outcome data
Selective reporting (reporting bias) Unclear risk Protocol not available; insufficient infor-
mation available to permit judgement
Other bias Low risk Study appears free of other bias
ABI: ankle-brachial index.
ABPI: ankle-brachial pressure index.
54Pentoxifylline for intermittent claudication (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
GI: gastrointestinal.
MI: myocardial infarction.
SFA: superficial femoral artery.
PAD: peripheral arterial disease.
ACD: absolute claudication distance.
WIQ: walking impairment questionnaire.
SF36: Short Form 36.
QoL: quality of life.
COAD: chronic occlusive artery disease.
tds: 3 times daily.
PFWD: pain-free walking distance.
SD: standard deviation.
TWD: total walking distance.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bieron 2005 Not double-blinded
Ciuffetti 1991 Looked at biochemical properties, not TWD or PFWD
Dawson 1999 Single-blinded study
Dettori 1989 Single-blinded for acenocoumarol; therefore no true double-blinding of all trial agents. Outcomes measured in
time, not distance
Ehrly 1986 Different outcome measures such as muscle tissue O2 pressure
Ehrly 1987 Different outcome measures such as muscle tissue O2 pressure
Farkas 1993 Duration of therapy only 2 weeks
Fossat 1995 Different outcome measures such as leucocyte activation
Guest 2005 Cost comparison with no clinical outcomes
Hepp 1996 Not double-blinded
Horowitz 1982 Variable doses of pentoxifylline
Incandela 2002 Looked at microcirculatory parameters
Kellner 1976 Participants with Fontaine stage II and III; results for the 2 groups not presented separately
Luk’Janov 1995 Different outcome measures such as haemorheologic and haemodynamic measures evaluated; minimal data on
walking distance
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(Continued)
Milio 2003 Not double-blinded
Milio 2006 Single-blinded study
Panchenko 1997 Open study - no blinding
Pignoli 1985 Not double-blinded
Poggesi 1985 Different outcomes such as circulatory changes and prostaglandin synthesis
Regenthal 1991 Not double-blinded
Reilly 1987 All included participants single-blinded after first 8 weeks; therefore no true randomisation
Rodin 1998 Not a double-blinded clinical trial
Rodin 1998a Not a double-blinded clinical trial
Roekaerts 1984 Participants with Fontaine stage II and III; results not presented separately for the 2 groups
Rudofsky 1987 Only 1 to 2 weeks of treatment provided
Rudofsky 1988 Only 2 weeks of treatment provided
Rudofsky 1989 Only 2 weeks of treatment provided
Scheffler 1991 Not a double-blinded study. Training for participants provided
Scheffler 1994 Not a double-blinded study. Comparison with exercise performed
Schubotz 1976 Participants with symptoms of critical limb ischaemia
Shustov 1997 Open controlled trial
Singh 2009 Open study
Strano 1984 Participants with stage Fontaine stage II and III; results not presented separately for the 2 groups
Strano 2002 Open study
Thomson 1990 Participants with symptoms of critical limb ischaemia
Tonak 1977 Participants with Fontaine stage II and III; results not presented separately for the 2 groups
Triebe 1992 Open study
Tsang 1994 Different outcome measures such as albumin/creatinine ratio, etc
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(Continued)
Wang 2003 Different outcome measures such as lipoprotein cholesterol concentrations
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. PFWD data for comparisons of pentoxifylline versus placebo
Study Dose
Dur Pxt Plc Px0 SD Px-E SD
%age SD%
Plc0 SD Plc-
E
SD
%age SD%
Diff
Ce-
sarone
2002b
1600
40 88 90 43 70 166 220 286.
0
42 10 155 440 269.
0
17.0
Crea-
ger
2008
1200
24 86 84 118 83 34.3 120 88 21.2 13.1
Daw-
son
2000
1200
24 232 239 126 79 202 139 60.3 122 69 180 115 47.5 12.8
Don-
ald-
son
1984
600 8 40 40 108.
2
85.1 119.
3
73.7 10.3 97.1 66.2 129 109.
4
32.9 -22.
6
Ernst
1992
1200
12 20 20 144 54 364 236 152.
8
134 64 384 228 186.
6
-33.
8
Gal-
lus
1985
cross-
over
phase
I*
1200
8 19 19 27.1 47.7 76.0 28.7 48.3 68.2 7.8
Kiesewet-
ter
1988
1200
8 20 20 (+44
m)
43.6 (+3
m)
3.1 40.5
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Table 1. PFWD data for comparisons of pentoxifylline versus placebo (Continued)
Lindgarde
1989
1200
26 76 74 77 4 80 12 79 4 60 11 20
Porter
1982a
1200
24 40 42 111 195 76 117 180 54 22
Porter
1982b
1200
24 11 11 54.7 114.
2
108.
8
100.
8
136 34.9 73.9
Volker
1978
1200
4 25 25 331.
2
22.7 464.
6
23.
60
40.3 230.
4
15.0 290.
2
16.9 25.9 14.4
Dur: duration in weeks.
Pxt: pentoxifylline sample size.
Plc: placebo sample size.
Px0: baseline walking distance in meters for pentoxifylline group.
SD: standard deviation.
Px-E: end walking distance in meters for pentoxifylline group.
%age: percentage improvement in walking distance.
SD%: standard deviation percentage improvement in walking distance.
Plc0: baseline walking distance in meters for placebo group.
Plc-E: end walking distance in meters for placebo group.
Diff: difference in percentage of improvement for pentoxifylline and placebo groups.
*: data presented for phase I only.
Table 2. TWD data for comparisons of pentoxifylline versus placebo
Study Dose
Dur Pxt Plc Px0 SD Px-E SD
%age SD%
Plc0 SD Plc-
E
SD
%age SD%
Diff
Bel-
caro
2002
1600
24 27 26 56 8 161 21 187.
5
59 12 103 22 74.6 112.
9
Bollinger
1977
600 8 10 9 226 33.6 697 125.
3
208.
0
177 29.2 270 201.
8
52.5 155.
9
Ce-
sarone
2002b
1600
40 88 90 87 11 287 340 229.
9
98 14 180 120 83.7 146.
2
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Table 2. TWD data for comparisons of pentoxifylline versus placebo (Continued)
Crea-
ger
2008
1200
24 86 84 316 191 13.9 292 161 3.3 10.6
Daw-
son
2000
1200
24 232 239 238 119 308 183 29.4 234 119 300 180 28.2 1.2
De
Sanc-
tis
2002a
1800
52 56 45 66 13 267 38 304.
5
67 11 188 19 180.
6
123.
9
De
Sanc-
tis
2002b
1800
52 75 60 554 66 943 78 70.2 576 71 755 67 31.1 39.1
Di
Perri
1983
cross-
over
phase
I*
1200
8 12 12 223 20 359 29 61.
00
208 24.6 215 25 3.4 57.6
Ernst
1992
1200
12 20 20 166 58 504 257 203.
6
151 58 420 229 178.
14
25.5
Gal-
lus
1985
cross-
over
phase
I*
1200
8 19 19 67.8 90.4 33.3 87.9 99.8 13.5 19.8
Lee
2001
800 8 17 16 114 51 147 81 28.9 116 56 121 62 4.3 24.6
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Table 2. TWD data for comparisons of pentoxifylline versus placebo (Continued)
Lindgarde
1989
1200
26 76 74 132 9 50.0 9 155 11 29.0 8 21.0
Porter
1982a
1200
24 42 40 172 268 55.8 181 250 38.1 17.7
Porter
1982b
1200
24 11 11 92.1 156 69.4 182.
1
187.
4
2.9 66.5
Dur: duration in weeks.
Pxt: pentoxifylline sample size.
Plc: placebo sample size.
Px0: baseline walking distance in meters for pentoxifylline group.
SD: standard deviation.
Px-E: end walking distance in meters for pentoxifylline group.
%age: percentage improvement in walking distance.
SD%: standard deviation percentage improvement in walking distance.
Plc0: baseline walking distance in meters for placebo group.
Plc-E: end walking distance in meters for placebo group.
Diff: difference in percentage of improvement for pentoxifylline and placebo groups.
*: data presented for phase I only.
Table 3. PFWD data for comparisons of pentoxifylline versus other treatments
Study
Dose Dur Pxt Oth Px0 SD Px-E SD %age Oth0 SD Oth-E SD %age Diff
Bohmer
1988
Gingko
biloba
1200 24 13 14 80.1 325.6 306.5 94.6 327.5 246.2 60.3
Cha-
con-
Quevedo
1994
Bu-
flomedil
1200 13 15 15 109 63 194 72 78.0 97 73 160 73 64.9 13.1
Cha-
con-
Quevedo
1200 13 15 15 109 63 194 72 78.0 109 56 194 65 78.0 0
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Table 3. PFWD data for comparisons of pentoxifylline versus other treatments (Continued)
1994
Nifedip-
ine
Crea-
ger
2008*
Ilo-
prost
1200 24 86 87 34.3 31.2 3.1
Daw-
son
2000
Cilosta-
zol
1200 24 232 227 126 79 202 139 60.3 124 81 218 149 75.8 -15.5
Hepp
1992
PGE1
400 4 98 97 72 133 84.7 80 175 118.8 -34.1
Per-
honiemi
1984
Flu-
nar-
izine
cross-
over
1200 12 31 31 135 160 18.5 135 16 19 0
Schel-
long
2012
PGE1
1200 8 285 276 1.98** 3.61 2.60** 12.22
*highest dose group iloprost.
**PFWD reported as ratio of distance after 8 weeks of treatment compared with baseline.
Dur: duration in weeks.
Pxt: pentoxifylline sample size.
Oth: other treatment group sample size.
Px0: baseline walking distance in meters for pentoxifylline group.
SD: standard deviation.
Px-E: end walking distance in meters for pentoxifylline group.
%age: percentage improvement in walking distance.
Oth0: baseline walking distance in meters for other treatment group.
Oth-E: end walking distance in meters for other treatment group.
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Diff: difference in percentage improvement for pentoxifylline and other treatment groups.
Table 4. TWD data for comparisons of pentoxifylline versus other treatments
Study
Dose Dur Pxt Oth Px0 SD Px-E SD %age Oth0 SD Oth-E SD %age Diff
Ac-
cetto
1982
Nylidrin
HCL
1200 8 23 24 132.6 193.4 45.9 163.4 168.9 3.4 42.5
Bohmer
1988
Gingko
biloba
1200 24 13 14 189.5 427.3 125.5 203 436.5 115.0 10.5
Cha-
con-
Quevedo
1994
Bu-
flomedil
1200 13 15 15 180 67 226 57 25.6 159 76 205 66 28.9 -3.3
Cha-
con-
Quevedo
1994
Nifedip-
ine
1200 13 15 15 180 67 226 57 25.6 186 54 226 49 21.5 4.1
Cio-
con
1997
As-
pirin
1200 6 45 45 1 mile 2
miles
100 0.8
miles
1.2
miles
50 50
Crea-
ger
2008
Ilo-
prost*
1200 24 86 87 13.9 11.2 2.7
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Table 4. TWD data for comparisons of pentoxifylline versus other treatments (Continued)
Daw-
son
2000
Cilosta-
zol
1200 24 232 227 238 119 308 183 29.4 241 123 350 209 45.2 -15.8
Hepp
1992
PGE1
400 4 98 97 115 190 65.2 129 230 78.3 -13.1
Lee
2001
Cilosta-
zol
800 8 17 17 114 51 147 81 28.9 111 30 145 53 30.6 -1.7
Per-
honiemi
1984
Flu-
nar-
izine
cross-
over
1200 12 31 31 255 18 255 43 -25
Schel-
long
2012
PGE1
1200 8 285 276 1.76** 1.78 1.64** 0.86
*highest dose group iloprost.
**TWD reported as ratio of distance after 8 weeks of treatment compared with baseline.
Dur: duration in weeks.
Pxt: pentoxifylline sample size.
Oth: other treatment group sample size.
Px0: baseline walking distance in meters for pentoxifylline group.
SD: standard deviation.
Px-E: end walking distance in meters for pentoxifylline group.
%age: percentage improvement in walking distance.
Oth0: baseline walking distance in meters for other treatment group.
Oth-E: end walking distance in meters for other treatment group.
Diff: difference in percentage improvement for pentoxifylline and other treatment groups.
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A P P E N D I C E S
Appendix 1. CRS search strategy
#1 MESH DESCRIPTOR Arteriosclerosis 863
#2 MESH DESCRIPTOR Arteriolosclerosis EXPLODE ALL
TREES
0
#3 MESH DESCRIPTOR Arteriosclerosis Obliterans 69
#4 MESH DESCRIPTOR Atherosclerosis 489
#5 MESH DESCRIPTOR Arterial Occlusive Diseases 695
#6 MESH DESCRIPTOR Intermittent Claudication 664
#7 MESH DESCRIPTOR Ischemia 718
#8 MESH DESCRIPTOR Peripheral Vascular Diseases EX-
PLODE ALL TREES
2072
#9 (atherosclero* or arteriosclero* or PVD or PAOD or PAD ):
TI,AB,KY
7440
#10 ((arter* or vascular or vein* or veno* or peripher*) near3 (oc-
clus* or reocclus* or re-occlus* or steno* or restenos* or ob-
struct* or lesio* or block* or harden* or stiffen* or obliter*) ):
TI,AB,KY
6179
#11 (peripheral near3 dis*):TI,AB,KY 2717
#12 (claudic* or IC):TI,AB,KY 2472
#13 (isch* or CLI):TI,AB,KY 18739
#14 arteriopathic:TI,AB,KY 7
#15 dysvascular*:TI,AB,KY 9
#16 (leg near3 (occlus* or reocclus* or re-occlus* or steno* or
restenos* or obstruct* or lesio* or block* or harden* or stiffen*
or obliter*) ):TI,AB,KY
75
#17 (limb near3 (occlus* or reocclus* or re-occlus* or steno* or
restenos* or obstruct* or lesio* or block* or harden* or stiffen*
or obliter*) ):TI,AB,KY
110
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(Continued)
#18 ((lower near3 extrem*) near3 (occlus* or reocclus* or re-oc-
clus* or steno* or restenos* or obstruct* or lesio* or block* or
harden* or stiffen* or obliter*) ):TI,AB,KY
70
#19 ((iliac or femoral or popliteal or femoro* or fempop* or crural)
near3(occlus* or reocclus* or re-occlus* or steno* or restenos*
or obstruct* or lesio* or block* or harden* or stiffen* or
obliter*) ):TI,AB,KY
734
#20 MESHDESCRIPTOR Leg EXPLODE ALL TREESWITH
QUALIFIERS BS
1061
#21 MESH DESCRIPTOR Iliac Artery 135
#22 MESH DESCRIPTOR Popliteal Artery 246
#23 MESH DESCRIPTOR Femoral Artery 723
#24 MESH DESCRIPTOR Tibial Arteries 30
#25 (((femor* or iliac or popliteal or fempop* or crural or poplite*
or infrapopliteal or inguinal or femdist* or inguinal or infrain-
quinal or tibial) near3 (occlus* or reocclus* or re-occlus* or
steno* or restenos* or obstruct* or lesio* or block* or harden*
or stiffen* or obliter*) )):TI,AB,KY
858
#26 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR
#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR
#16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR
#23 OR #24 OR #25
35405
#27 MESH DESCRIPTOR Pentoxifylline EXPLODE ALL
TREES
408
#28 (pentox* OR oxypent*):TI,AB,KY 871
#29 MESH DESCRIPTOR Phosphodiesterase Inhibitors EX-
PLODE ALL TREES
4914
#30 (phosphodiesterase near2 inhibitor*):TI,AB,KY 1286
#31 BL-191:TI,AB,KY 5
#32 #27 OR #28 OR #29 OR #30 OR #31 5708
#33 #26 AND #32 703
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WH A T ’ S N E W
Last assessed as up-to-date: 8 April 2015.
Date Event Description
4 May 2015 New search has been performed Searches rerun. One new study excluded and one study
that was previously recorded as ’Ongoing’ now recorded
as an included study
4 May 2015 New citation required but conclusions have not changed Searches rerun. One new study excluded and one study
that was previously recorded as ’Ongoing’ now recorded as
an included study, with limited data available from Clin-
icalTrials.gov (comparison pentoxifylline vs PGE1). New
author added to the review team.Conclusions not changed
H I S T O R Y
Protocol first published: Issue 2, 2005
Review first published: Issue 1, 2012
Date Event Description
22 October 2008 Amended Converted to new review format
C O N T R I B U T I O N S O F A U T H O R S
For this review update:
RF evaluated studies for inclusion, performed data extraction, assessed risk of bias and updated manuscript text.
KS evaluated studies for inclusion, performed data extraction and assessed risk of bias.
ES, MAH, AB and JM provided editorial support.
D E C L A R A T I O N S O F I N T E R E S T
JM: Chair of NICE guideline development group for PAD and co-author of several cited papers (Meng 2014; Squires 2010; Squires
2011; Stevens 2012).
KS: none known
RF: none known
ES: none known
MAH: none known
AB: none known
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JM: Professor Michaels has received programme funding from the NIHR for research related to vascular disease and has received
payments for secondment for committee work from the HTA Prioritisation Panel and the NICE Appraisal Committee, for consultancy
fromMichaels Consulting Limited (as director of company that provides consultancy for a number of companies - none directly related
to the subject of this review) and for a review of practice guidelines from KCE (Belgian Health Care Knowledge Centre)
S O U R C E S O F S U P P O R T
Internal sources
• Sheffield Vascular Institute, Northern General Hospital, Sheffield Teaching Hospital, UK.
• School of Health and Related Research (ScHARR), University of Sheffield, UK.
External sources
• Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government, UK.
The Cochrane Vascular editorial base is supported by the Chief Scientist Office.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
To adhere to updated Cochrane guidelines for assessment of bias, we have included an assessment of bias performed using the ’Risk of
bias’ tool of The Cochrane Collaboration and have removed the Jadad score.
We have removed eight studies from the ’Excluded studies’ presented in the previous version of this review, as they were considered not
relevant in the light of current Cochrane guidelines.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Intermittent Claudication [∗drug therapy]; Pentoxifylline [∗therapeutic use]; Platelet Aggregation Inhibitors [∗therapeutic use]; Ran-
domized Controlled Trials as Topic; Vasodilator Agents [∗therapeutic use]; Walking
MeSH check words
Humans
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